Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Breast Cancer Res Treat Retrieve available abstracts of 504 articles: HTML format

Single Articles

July 2025
1. RING A, Sutherland S, Harper-Wynne C, Owen J, et al
   A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable LA/MBC: final results of the ESTHER study.
   Breast Cancer Res Treat. 2025;212:113-121.
   PubMed     Abstract available
   
   
   
2. NIERENBERG TC, Thomas SM, Halliday I, Botty van den Bruele A, et al
   Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study.
   Breast Cancer Res Treat. 2025;212:161-172.
   PubMed     Abstract available
   
   
   
3. COSAR R, Sut N
   Our response to the letter to the editor for the article "Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis".
   Breast Cancer Res Treat. 2025;212:185-186.
   PubMed     Abstract available
   
   
   
4. JASPER JM, Vora H, Kantor O, McGrath M, et al
   Management of ipsilateral breast tumor recurrence after prior breast conservation therapy.
   Breast Cancer Res Treat. 2025;212:361-369.
   PubMed     Abstract available
   
   
   
5. AKTAS A, Gurleyik MG, Akkus D, Ucur Z, et al
   Invasive lobular breast carcinoma variants; clinicopathological features and patient outcomes.
   Breast Cancer Res Treat. 2025;212:347-359.
   PubMed     Abstract available
   
   
   
6. YAO J, Zhou W, Jia X, Zhu Y, et al
   Machine learning prediction of pathological complete response to neoadjuvant chemotherapy with peritumoral breast tumor ultrasound radiomics: compare with intratumoral radiomics and clinicopathologic predictors.
   Breast Cancer Res Treat. 2025;212:325-336.
   PubMed     Abstract available
   
   
   
7. YI ZL, Yang BB, Zhang JN, Zhao MJ, et al
   Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review.
   Breast Cancer Res Treat. 2025;212:189-193.
   PubMed     Abstract available
   
   
   June 2025
8. LIUTTI VT, do Vale DL, de Souza BL, Manea RRF, et al
   Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis.
   Breast Cancer Res Treat. 2025 Jun 13. doi: 10.1007/s10549-025-07746.
   PubMed     Abstract available
   
   
   
9. HANNOUN-LEVI JM, Strnad V, Polgar C
   Local treatment of ipsilateral breast cancer recurrence: a sensitive decision-making process.
   Breast Cancer Res Treat. 2025 Jun 12. doi: 10.1007/s10549-025-07761.
   PubMed    
   
   
   
10. SHIN E, Cha YJ, Kim HM, Koo JS, et al
    PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis.
    Breast Cancer Res Treat. 2025 Jun 11. doi: 10.1007/s10549-025-07757.
    PubMed     Abstract available
    
    
    
11. STENMARK TULLBERG A, Thurfjell V, Kovacs A, Micke P, et al
    Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial.
    Breast Cancer Res Treat. 2025 Jun 9. doi: 10.1007/s10549-025-07744.
    PubMed     Abstract available
    
    
    
12. ULENE SR, Wang S, Cook JR, McAuley F, et al
    Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer.
    Breast Cancer Res Treat. 2025 Jun 4. doi: 10.1007/s10549-025-07745.
    PubMed     Abstract available
    
    
    
13. LEE KT, Hu B, Martinez Tyson D, Geiss C, et al
    A mixed-methods study characterizing experiences of medical oncologists' use of gonadotropin-releasing hormone agonists for treatment of breast cancer.
    Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07734.
    PubMed     Abstract available
    
    
    
14. COHEN LN, Rogers CC, Lloren JIC, Kamaraju S, et al
    National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016-2021: The impact of the KATHERINE trial.
    Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07750.
    PubMed     Abstract available
    
    
    
15. WING SE, Liu Y, Zheng F, Hamm NC, et al
    Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer.
    Breast Cancer Res Treat. 2025 Jun 3. doi: 10.1007/s10549-025-07735.
    PubMed     Abstract available
    
    
    
16. DING K, Chen L, Levine KM, Sikora MJ, et al
    FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role.
    Breast Cancer Res Treat. 2025;211:501-515.
    PubMed     Abstract available
    
    
    
17. HAN R, Brogi E, Thompson D, El-Tamer M, et al
    Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience.
    Breast Cancer Res Treat. 2025;211:449-454.
    PubMed     Abstract available
    
    
    
18. BOTTY VAN DEN BRUELE A, Ren Y, Thomas SM, Ntowe KW, et al
    High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old.
    Breast Cancer Res Treat. 2025;211:421-429.
    PubMed     Abstract available
    
    
    
19. COLCIAGO RR, Ferrario F, Chissotti C, Rossano G, et al
    Long-term outcomes of volume de-escalation for breast nodal irradiation.
    Breast Cancer Res Treat. 2025;211:375-384.
    PubMed     Abstract available
    
    
    
20. DUGGIRALA N, Zhang S, Master A, Rao R, et al
    Biology, care, and outcomes of gestational breast cancers: a review.
    Breast Cancer Res Treat. 2025;211:547-559.
    PubMed     Abstract available
    
    
    
21. NEWMAN AM, Daly AE, Anderman KJ, Dang PA, et al
    Timing of radiofrequency identification tag placement: can early placement save time and patient experience?
    Breast Cancer Res Treat. 2025;211:669-674.
    PubMed     Abstract available
    
    
    
22. ZHANG C, Liu J, Gu T, Meng X, et al
    Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation.
    Breast Cancer Res Treat. 2025;211:637-648.
    PubMed     Abstract available
    
    
    
23. BUZATTO IPC, Recife SA, Miguel L, Bonini RM, et al
    Machine learning can reliably predict malignancy of breast lesions based on clinical and ultrasonographic features.
    Breast Cancer Res Treat. 2025;211:581-593.
    PubMed     Abstract available
    
    
    
24. WEHBE A, Katlin F, Sharma E, Hans M, et al
    Breast imaging recommendations for young females (age < 40 years) with >/= 20% lifetime breast cancer risk: practice patterns at a specialized clinic.
    Breast Cancer Res Treat. 2025 Jun 1. doi: 10.1007/s10549-025-07738.
    PubMed     Abstract available
    
    
    May 2025
25. MUSTAFA NM, Mustafa MT, Abushanab AK, Alakhras HM, et al
    Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2025 May 31. doi: 10.1007/s10549-025-07737.
    PubMed     Abstract available
    
    
    
26. BADER G, Quintanilha JCF, Veney D, Graf RP, et al
    Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study.
    Breast Cancer Res Treat. 2025 May 30. doi: 10.1007/s10549-025-07740.
    PubMed     Abstract available
    
    
    
27. MEDFORD AJ, Velimirovic M, Gefen Y, Niemierko A, et al
    Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
    Breast Cancer Res Treat. 2025 May 29. doi: 10.1007/s10549-025-07710.
    PubMed     Abstract available
    
    
    
28. GEMMILL JAL, Thompson P, Batiste R, Vacchi-Suzzi C, et al
    Metastatic breast cancer through the Oncotype DX Breast Recurrence Score(R): insights from a small cohort study.
    Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07736.
    PubMed     Abstract available
    
    
    
29. SPRIET J, Miled AB, Mailliez A, Bonnier S, et al
    Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and performance of ultrafast sequences.
    Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07650.
    PubMed     Abstract available
    
    
    
30. FREITAS AJA, Causin RL, Calfa S, Santana IVV, et al
    Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes.
    Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07718.
    PubMed     Abstract available
    
    
    
31. SIREK A, Sirek T, Nowakowski R, Borawski P, et al
    Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes.
    Breast Cancer Res Treat. 2025 May 27. doi: 10.1007/s10549-025-07732.
    PubMed     Abstract available
    
    
    
32. KOSTOV AM, Jensen MB, Ejlertsen B, Thomassen M, et al
    Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.
    Breast Cancer Res Treat. 2025 May 23. doi: 10.1007/s10549-025-07726.
    PubMed     Abstract available
    
    
    
33. GRACIANO N, Lopez L, Rodriguez CA, Montoya K, et al
    Effect of chemotherapy timing in triple-negative breast cancer: a real-world evidence study.
    Breast Cancer Res Treat. 2025 May 21. doi: 10.1007/s10549-025-07716.
    PubMed     Abstract available
    
    
    
34. WADDEN E, Yogeswaran V, Ray RM, Vasbinder A, et al
    Social determinants of cardiovascular disease in women with and without breast cancer.
    Breast Cancer Res Treat. 2025 May 21. doi: 10.1007/s10549-025-07731.
    PubMed     Abstract available
    
    
    
35. LORENTZEN EH, Chen YJ, Jones AL, Kantor O, et al
    Omission of multimodal therapy in older adults with high-risk breast cancer.
    Breast Cancer Res Treat. 2025 May 20. doi: 10.1007/s10549-025-07728.
    PubMed     Abstract available
    
    
    
36. ARIF S, Muhammad N, Ang BH, Naeemi H, et al
    Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients.
    Breast Cancer Res Treat. 2025 May 20. doi: 10.1007/s10549-025-07724.
    PubMed     Abstract available
    
    
    
37. PEREZ-MORENO E, Ortega-Hernandez V, Zavala VA, Gamboa J, et al
    Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in ZEB1 expression.
    Breast Cancer Res Treat. 2025 May 18. doi: 10.1007/s10549-025-07723.
    PubMed     Abstract available
    
    
    
38. ARRATO NA, Soo MS, Wren AA, Stalls JM, et al
    Impact of loving-kindness meditation intervention vs. music intervention during biopsy on adherence to recommended breast cancer screening.
    Breast Cancer Res Treat. 2025 May 16. doi: 10.1007/s10549-025-07721.
    PubMed     Abstract available
    
    
    
39. HADIDCHI R, Duong KS, Hou J, Maldjian T, et al
    COVID-19 pandemic interruption of breast cancer screening is linked to clinical upstaging at presentation: the roles of demographics, socioeconomic status and unmet social needs.
    Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07713.
    PubMed     Abstract available
    
    
    
40. BECK AS, Earley M, Troxell M, Tsai J, et al
    Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07722.
    PubMed     Abstract available
    
    
    
41. AJJAWI I, Rios A, Wei W, Park TS, et al
    Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer.
    Breast Cancer Res Treat. 2025 May 15. doi: 10.1007/s10549-025-07725.
    PubMed     Abstract available
    
    
    
42. WOOLPERT KM, Ahern TP, Baurley JW, Maliniak ML, et al
    Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients.
    Breast Cancer Res Treat. 2025 May 14. doi: 10.1007/s10549-025-07719.
    PubMed     Abstract available
    
    
    
43. WOOSTER M, Chen L, Accordino MK, Sathe C, et al
    Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.
    Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07714.
    PubMed     Abstract available
    
    
    
44. IWAI C, Miyawaki A, Konishi T, Okada A, et al
    Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis.
    Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07720.
    PubMed     Abstract available
    
    
    
45. RADWAN RM, Schuster ALR, Hertz DL, Lustberg MB, et al
    Tolerance for chemotherapy-induced peripheral neuropathy among women with metastatic breast cancer: a discrete-choice experiment.
    Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07715.
    PubMed     Abstract available
    
    
    
46. HEGER PW, Hotz D, Kalder M, Kostev K, et al
    Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.
    Breast Cancer Res Treat. 2025 May 13. doi: 10.1007/s10549-025-07711.
    PubMed     Abstract available
    
    
    
47. KOOIJMAN MML, Hage JJ, Scholten AN, van Duijnhoven FH, et al
    Advantages of immediate implant-based breast reconstruction over delayed breast reconstruction in women treated with postmastectomy radiotherapy for breast cancer.
    Breast Cancer Res Treat. 2025 May 12. doi: 10.1007/s10549-025-07690.
    PubMed     Abstract available
    
    
    
48. JANKOWSKI C, Houvenaeghel G, Renaudeau C, Leveque J, et al
    How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
    Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07642.
    PubMed     Abstract available
    
    
    
49. GULTEKIN SC, Karadibak D, Cakir AB, Guc ZG, et al
    Self-administered versus lymphedema therapist-administered complex decongestive therapy protocol in breast cancer-related lymphedema: a non-inferiority randomized controlled trial with three-month follow-up.
    Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07709.
    PubMed     Abstract available
    
    
    
50. 
    2024 RISE UP for breast cancer abstract collection.
    Breast Cancer Res Treat. 2025 May 6. doi: 10.1007/s10549-025-07692.
    PubMed    
    
    
    
51. LEE SF, Wong HCY, Robijns J, Ciocon SLB, et al
    Chronic skin toxicities in breast cancer survivors: a systematic review and meta-analysis of radiotherapy techniques.
    Breast Cancer Res Treat. 2025 May 5. doi: 10.1007/s10549-025-07700.
    PubMed     Abstract available
    
    
    
52. WOCKEL A, Park-Simon TW, Korfel A, Raab K, et al
    Correction: Preferences of patients with high-risk HR+/HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany.
    Breast Cancer Res Treat. 2025;211:273-275.
    PubMed    
    
    
    
53. OZEN A, Halici M
    Letter to the editor regarding the article "Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis".
    Breast Cancer Res Treat. 2025;211:271-272.
    PubMed     Abstract available
    
    
    
54. POELHEKKEN K, Dorrius MD, Dibden A, Duffy SW, et al
    The natural history of ductal carcinoma in situ: development, validation, and estimated outcomes of the SimDCIS model.
    Breast Cancer Res Treat. 2025;211:223-231.
    PubMed     Abstract available
    
    
    
55. SAFGREN SL, Suman VJ, Leon Ferre RA, Kosel ML, et al
    The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.
    Breast Cancer Res Treat. 2025;211:261-270.
    PubMed     Abstract available
    
    
    
56. HEINDL F, Schiel J, Hack CC, Amann N, et al
    Malignant upgrade in lesions of uncertain malignant potential in the breast (B3 lesions) - is open excision always necessary?
    Breast Cancer Res Treat. 2025;211:173-183.
    PubMed     Abstract available
    
    
    
57. KHUBCHANDANI JA, Kc M, Dey P, Proussaloglou EM, et al
    Racial and ethnic disparities in conversion to mastectomy following lumpectomy.
    Breast Cancer Res Treat. 2025;211:99-110.
    PubMed     Abstract available
    
    
    
58. PADILLA DB, Tsai J, Beck AS, Wapnir IL, et al
    Lumpectomy surgery for large ductal carcinoma in situ.
    Breast Cancer Res Treat. 2025;211:51-58.
    PubMed     Abstract available
    
    
    
59. FRIEDEWALD SM, Sieniek M, Jansen S, Mahvar F, et al
    Triaging mammography with artificial intelligence: an implementation study.
    Breast Cancer Res Treat. 2025;211:1-10.
    PubMed     Abstract available
    
    
    April 2025
60. MAURER C, Agostinetto E, Ameye L, Lambertini M, et al
    Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.
    Breast Cancer Res Treat. 2025 Apr 28. doi: 10.1007/s10549-025-07699.
    PubMed     Abstract available
    
    
    
61. SANVISENS A, Vidal-Vila A, Puigdemont M, Vinas G, et al
    Population-based analysis of breast cancer incidence and mortality: overall and age-specific temporal trends over 40-year period in Girona, Spain.
    Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07704.
    PubMed     Abstract available
    
    
    
62. VIDULA N, Blouch E, Hesler K, Niemierko A, et al
    Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA.
    Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07705.
    PubMed     Abstract available
    
    
    
63. WILKERSON AD, Obi M, Gentle C, Wei W, et al
    First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer.
    Breast Cancer Res Treat. 2025 Apr 25. doi: 10.1007/s10549-025-07703.
    PubMed     Abstract available
    
    
    
64. FEST SN, Farland LV, Doody DR, Eliassen AH, et al
    Correction: Hormone-associated dietary patterns and premenopausal breast cancer risk.
    Breast Cancer Res Treat. 2025 Apr 24. doi: 10.1007/s10549-025-07706.
    PubMed    
    
    
    
65. PERDRIX A, Olympios N, Rouvet J, Degremont M, et al
    Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy.
    Breast Cancer Res Treat. 2025 Apr 22. doi: 10.1007/s10549-025-07702.
    PubMed     Abstract available
    
    
    
66. ISIK B, Davey MG, Jaffer AA, Buckley J, et al
    Correction: Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.
    Breast Cancer Res Treat. 2025 Apr 18. doi: 10.1007/s10549-025-07698.
    PubMed    
    
    
    
67. GHOLAMI S, Saffarfar H, Mehraban MR, Ardabili NS, et al
    Targeting breast cancer: the promise of phage-based nanomedicines.
    Breast Cancer Res Treat. 2025 Apr 17. doi: 10.1007/s10549-025-07696.
    PubMed     Abstract available
    
    
    
68. LAU C, LaBorde K, Fatima B, Alfartosy SS, et al
    Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2025 Apr 16. doi: 10.1007/s10549-025-07701.
    PubMed     Abstract available
    
    
    
69. SHIGEMATSU H, Takaya M, Suzuki K, Fujimoto M, et al
    Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2025 Apr 12. doi: 10.1007/s10549-025-07697.
    PubMed     Abstract available
    
    
    
70. MCQUEEN SRA, Chin WQ, Cunliffe HE, McDonald FJ, et al
    Stable overexpression of the epithelial sodium channel alpha subunit reduces migration and proliferation in breast cancer cells.
    Breast Cancer Res Treat. 2025 Apr 12. doi: 10.1007/s10549-025-07667.
    PubMed     Abstract available
    
    
    
71. TURKOGLU E, Akdag Topal G, Yildirim S, Kinikoglu O, et al
    Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer.
    Breast Cancer Res Treat. 2025 Apr 11. doi: 10.1007/s10549-025-07694.
    PubMed     Abstract available
    
    
    
72. CHIEN YN, Lin LY, Lin YC, Hsieh YC, et al
    Correction: Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019.
    Breast Cancer Res Treat. 2025 Apr 10. doi: 10.1007/s10549-025-07691.
    PubMed    
    
    
    
73. DIAO B, Cai Y, Song D, Hu Y, et al
    A potential therapeutic molecule target: lncRNA AK023507 inhibits the metastasis of breast cancer by regulating the WNT/DOCK4/beta-catenin axis.
    Breast Cancer Res Treat. 2025 Apr 9. doi: 10.1007/s10549-025-07695.
    PubMed     Abstract available
    
    
    
74. HIDAKA K, Goto-Yamaguchi L, Sueta A, Tomiguchi M, et al
    Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2025 Apr 9. doi: 10.1007/s10549-025-07693.
    PubMed     Abstract available
    
    
    
75. JUNG W, Hubbard RA, Smith AM, Ko K, et al
    Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial.
    Breast Cancer Res Treat. 2025 Apr 2. doi: 10.1007/s10549-025-07636.
    PubMed     Abstract available
    
    
    
76. POTRONY M, Morales-Romero B, Moreno L, Pastor B, et al
    Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice.
    Breast Cancer Res Treat. 2025;210:507-519.
    PubMed     Abstract available
    
    
    
77. MAKINELI S, Vriens MR, van Diest PJ, Witkamp AJ, et al
    Intraductal laser ablation during ductoscopy in patients with pathological nipple discharge.
    Breast Cancer Res Treat. 2025;210:329-335.
    PubMed     Abstract available
    
    
    
78. CHEN Q, Elwood M, Campbell I, Cavadino A, et al
    Incidence trends of ductal carcinoma in situ in New Zealand women between 1999 and 2022.
    Breast Cancer Res Treat. 2025;210:439-449.
    PubMed     Abstract available
    
    
    
79. QIU ZX, Xie LY, Li YZ, Zhang ZC, et al
    L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study.
    Breast Cancer Res Treat. 2025;210:709-718.
    PubMed     Abstract available
    
    
    
80. ERIN N, Tavsan E, Haksever S, Yerlikaya A, et al
    Targeting BMP-1 enhances anti-tumoral effects of doxorubicin in metastatic mammary cancer: common and distinct features of TGF-beta inhibition.
    Breast Cancer Res Treat. 2025;210:563-574.
    PubMed     Abstract available
    
    
    
81. BAHL M, Kshirsagar A, Pohlman S, Lehman CD, et al
    Traditional versus modern approaches to screening mammography: a comparison of computer-assisted detection for synthetic 2D mammography versus an artificial intelligence algorithm for digital breast tomosynthesis.
    Breast Cancer Res Treat. 2025;210:529-537.
    PubMed     Abstract available
    
    
    
82. OZLER T, Cosar R, Sut N, Nurlu D, et al
    Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis.
    Breast Cancer Res Treat. 2025;210:673-686.
    PubMed     Abstract available
    
    
    
83. STUTZ K, Mason H, Niakan S, Coulter AP, et al
    The impact of surgical technique on the number of sentinel lymph nodes removed and its effect on complication rates.
    Breast Cancer Res Treat. 2025;210:605-613.
    PubMed     Abstract available
    
    
    
84. BAYRAM A, Bagbudar S, Karanlik H, Cabioglu N, et al
    Estrogen receptor positivity in stromal cells of the tumor bed predicts the response to neoadjuvant chemotherapy for breast carcinoma.
    Breast Cancer Res Treat. 2025;210:627-633.
    PubMed     Abstract available
    
    
    
85. KORPINEN K, Autere TA, Tuominen J, Loyttyniemi E, et al
    Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma.
    Breast Cancer Res Treat. 2025;210:463-475.
    PubMed     Abstract available
    
    
    
86. QI M, Gao S, Zhang Z, Lang R, et al
    Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit.
    Breast Cancer Res Treat. 2025;210:451-461.
    PubMed     Abstract available
    
    
    
87. BERLANGA L, Lotersztein V, Aranda EI, Cerretini R, et al
    Contribution of large genomic rearrangements in BRCA1/2 genes and CHEK2 1100delC allele variant to the development of breast/ovarian cancer in Argentinian population.
    Breast Cancer Res Treat. 2025;210:385-391.
    PubMed     Abstract available
    
    
    
88. SUMAN L, D'Ascoli E, Depretto C, Berenghi A, et al
    Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique.
    Breast Cancer Res Treat. 2025;210:417-423.
    PubMed     Abstract available
    
    
    
89. AL HASAN SM, Matthew KA, Toriola AT
    Education and mammographic breast density.
    Breast Cancer Res Treat. 2025;210:377-384.
    PubMed     Abstract available
    
    
    
90. TARIQ N, Dani S, Makhija P, Warren MV, et al
    Breast hamartomas associated with epithelial atypia and malignancy: are there specific clinical, radiological or pathological features that identify at risk patients?
    Breast Cancer Res Treat. 2025;210:393-404.
    PubMed     Abstract available
    
    
    
91. YOON KH, Ahn SH, Shin HC, Koh HW, et al
    Oncoplastic breast reconstruction with single-port laparoscopically harvested omental flap: insights from a ten-year tertiary center experience.
    Breast Cancer Res Treat. 2025;210:355-364.
    PubMed     Abstract available
    
    
    
92. ZAMBRANO-O YT, Mejia-Garcia A, Morales PD, Tsao HM, et al
    Inference of genetic ancestry from a multi-gene cancer panel in Colombian women with cancer.
    Breast Cancer Res Treat. 2025;210:251-259.
    PubMed     Abstract available
    
    
    March 2025
93. FEST SN, Farland LV, Doody DR, Eliassen AH, et al
    Hormone-associated dietary patterns and premenopausal breast cancer risk.
    Breast Cancer Res Treat. 2025 Mar 30. doi: 10.1007/s10549-025-07689.
    PubMed     Abstract available
    
    
    
94. BRAUN M, Hamann M, Hanusch C, Andrulat A, et al
    Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer.
    Breast Cancer Res Treat. 2025 Mar 28. doi: 10.1007/s10549-025-07685.
    PubMed     Abstract available
    
    
    
95. NIKSERESHT S, Shewell LK, Day CJ, Jennings MP, et al
    Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay.
    Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07672.
    PubMed     Abstract available
    
    
    
96. ZHANG W, Shi S, Hong Y
    Comment on ''patient preferences for CDK4/6 inhibitor treatments in HR + /HER2- early breast cancer: a discrete choice survey study''.
    Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07673.
    PubMed    
    
    
    
97. SUTTON AL, Zhao J, He J, Tossas KY, et al
    Examining factors associated with experiencing cardiac arrhythmias in Black and White breast cancer survivors who received anthracyclines or trastuzumab.
    Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07671.
    PubMed     Abstract available
    
    
    
98. SHINN E, Zahrieh D, DeMichele A, Zdenkowski N, et al
    Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
    Breast Cancer Res Treat. 2025 Mar 27. doi: 10.1007/s10549-025-07653.
    PubMed     Abstract available
    
    
    
99. MODI S, Zhang S, Byng D, Hunter S, et al
    Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study.
    Breast Cancer Res Treat. 2025 Mar 25. doi: 10.1007/s10549-025-07649.
    PubMed     Abstract available
    
    
    
100. SCHONBERG MA, Wolfson EA, Eliassen AH, Rosner BA, et al
     Population attributable risk of a competing-risk model for breast cancer and non-breast cancer death among women >/= 65 years.
     Breast Cancer Res Treat. 2025 Mar 25. doi: 10.1007/s10549-025-07683.
     PubMed     Abstract available
     
     
     
101. VENKATARAMAN J, Mokbel K
     Critical appraisal of a data mining model for predicting nodal response to neoadjuvant treatment in breast cancer.
     Breast Cancer Res Treat. 2025 Mar 21. doi: 10.1007/s10549-025-07686.
     PubMed    
     
     
     
102. LIU H, Kou F, Hu L, Sun J, et al
     Potential candidates for adjuvant olaparib treatment in operable breast cancer patients with germline BRCA1/2 pathogenic variants after neoadjuvant chemotherapy.
     Breast Cancer Res Treat. 2025 Mar 19. doi: 10.1007/s10549-025-07687.
     PubMed     Abstract available
     
     
     
103. WANG J, Katsaros D, Wang Z, Ma L, et al
     Mitochondrial tRNA fragment, mt-tRF-Tyr-GTA-001 (tRF-21-X3OJI8EWB), in breast cancer and its potential clinical implications.
     Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07682.
     PubMed     Abstract available
     
     
     
104. KRONEN EA, Chervu NL, Ng AP, Lee H, et al
     National trends and survival outcomes associated with non-guideline-concordant treatment of inflammatory breast cancer.
     Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07669.
     PubMed     Abstract available
     
     
     
105. GAO Y, Zhang X, Ding M, Fu Z, et al
     Targeting "don't eat me" signal: breast cancer immunotherapy.
     Breast Cancer Res Treat. 2025 Mar 18. doi: 10.1007/s10549-025-07659.
     PubMed     Abstract available
     
     
     
106. AHN JH, Lee SJ, Yang SH, Kim JY, et al
     Clinical treatment score post-5 years and survival benefit from extended endocrine therapy for breast cancer patients under and over 50 years of age.
     Breast Cancer Res Treat. 2025 Mar 17. doi: 10.1007/s10549-025-07679.
     PubMed     Abstract available
     
     
     
107. XIE LX, Liu Y, Yang YG, Wang JN, et al
     Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database.
     Breast Cancer Res Treat. 2025 Mar 14. doi: 10.1007/s10549-025-07665.
     PubMed     Abstract available
     
     
     
108. GHORBANI M, Namazi S, Dehghani M, Razi F, et al
     Identifying the potential mediators of pathological complete response to neoadjuvant chemotherapy among TACR1 gene polymorphisms: a study on breast cancer patients.
     Breast Cancer Res Treat. 2025 Mar 13. doi: 10.1007/s10549-025-07674.
     PubMed     Abstract available
     
     
     
109. BASMADJIAN RB, Xu Y, Quan ML, Lupichuk S, et al
     Evaluating PREDICT and developing outcome prediction models in early-onset breast cancer using data from Alberta, Canada.
     Breast Cancer Res Treat. 2025 Mar 12. doi: 10.1007/s10549-025-07654.
     PubMed     Abstract available
     
     
     
110. DE VIS JB, Wang C, Nguyen KV, Sun L, et al
     Body composition as a potential biomarker of recurrence risk in patients with triple-negative breast cancer.
     Breast Cancer Res Treat. 2025 Mar 11. doi: 10.1007/s10549-025-07675.
     PubMed     Abstract available
     
     
     
111. BELLINI A, Keegan THM, Li Q, Jacinto A, et al
     The effect of body mass index on breast cancer stage and breast cancer specific survival.
     Breast Cancer Res Treat. 2025 Mar 10. doi: 10.1007/s10549-025-07678.
     PubMed     Abstract available
     
     
     
112. ZHAN H, Antony VM, Tang H, Theriot J, et al
     PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence.
     Breast Cancer Res Treat. 2025 Mar 10. doi: 10.1007/s10549-025-07660.
     PubMed     Abstract available
     
     
     
113. LI L, Zhang Z, Huang N, Ren J, et al
     IGF1R activates FOXP3-beta-catenin signaling to promote breast cancer development.
     Breast Cancer Res Treat. 2025 Mar 7. doi: 10.1007/s10549-025-07663.
     PubMed     Abstract available
     
     
     
114. NAKAUCHI C, Masunaga N, Kagara N, Oshiro C, et al
     Development of a prediction model for ctDNA detection (Cir-Predict) in breast cancer.
     Breast Cancer Res Treat. 2025 Mar 7. doi: 10.1007/s10549-025-07647.
     PubMed     Abstract available
     
     
     
115. MCCANN KE, Osman N, Cannon J, Brent L, et al
     Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.
     Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07656.
     PubMed     Abstract available
     
     
     
116. JUNG W, Park SH, Park YM, Song YM, et al
     Correction: Weight change and cardiovascular disease incidence in breast cancer survivors: a nationwide cohort study.
     Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07655.
     PubMed    
     
     
     
117. 'T HART D, Marriott R, Stone J
     Perceptions of breast cancer risk after breast density notification in a population-based screening program.
     Breast Cancer Res Treat. 2025 Mar 6. doi: 10.1007/s10549-025-07662.
     PubMed     Abstract available
     
     
     
118. BERNSTEIN-MOLHO R, Haisraely O, Galper S, Abu-Shhada N, et al
     The impact of loco-regional treatment on ipsilateral breast cancer recurrence and outcomes in carriers of BRCA1/2 pathogenic variants.
     Breast Cancer Res Treat. 2025 Mar 5. doi: 10.1007/s10549-025-07658.
     PubMed     Abstract available
     
     
     
119. BRABENDER D, Hossino D, Kim S, Jayich M, et al
     Factors associated with locoregional recurrence after neoadjuvant chemotherapy for breast cancer in a safety-net medical center.
     Breast Cancer Res Treat. 2025 Mar 4. doi: 10.1007/s10549-025-07668.
     PubMed     Abstract available
     
     
     
120. HARDY ABELOOS C, Gurewitz J, Xiao J, Darvishian F, et al
     Is the risk of local recurrence higher for microinvasive breast cancer vs. early stage invasive breast cancer?
     Breast Cancer Res Treat. 2025 Mar 3. doi: 10.1007/s10549-025-07664.
     PubMed     Abstract available
     
     
     February 2025
121. KIM SH, Park GE, Bertrand KA, Sandler DP, et al
     Mammographic density as a predictor of invasive breast cancer and ductal carcinoma in situ in over six million South Korean women.
     Breast Cancer Res Treat. 2025 Feb 28. doi: 10.1007/s10549-025-07648.
     PubMed     Abstract available
     
     
     
122. SULLIVAN M, Lei X, Karuturi M, Malinowski C, et al
     Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer.
     Breast Cancer Res Treat. 2025 Feb 28. doi: 10.1007/s10549-025-07637.
     PubMed     Abstract available
     
     
     
123. TERVASMAKI A, Kumpula TA, Grip M, Koivuluoma S, et al
     Population-based study of recurrent DNA damage response gene variants in breast cancer cases.
     Breast Cancer Res Treat. 2025 Feb 26. doi: 10.1007/s10549-025-07634.
     PubMed     Abstract available
     
     
     
124. CHANDEKAR KR, Satapathy S, Dharmashaktu Y, Ballal S, et al
     Somatostatin receptor-targeted theranostics in patients with estrogen receptor-positive metastatic breast cancer-a prospective exploratory study.
     Breast Cancer Res Treat. 2025 Feb 26. doi: 10.1007/s10549-025-07651.
     PubMed     Abstract available
     
     
     
125. RANDALL ARMEL S, Malcolmson J, Volenik A, Maganti M, et al
     Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review.
     Breast Cancer Res Treat. 2025 Feb 22. doi: 10.1007/s10549-025-07646.
     PubMed     Abstract available
     
     
     
126. KIMURA T, Takami T, Piao Y, Wang M, et al
     Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims databas
     Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07640.
     PubMed     Abstract available
     
     
     
127. BANYS-PALUCHOWSKI M, Hartmann S, Basali T, Gasparri ML, et al
     Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.
     Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07635.
     PubMed     Abstract available
     
     
     
128. DING X, Wang Q, Kan H, Zhao F, et al
     The regulation mechanism of perceived stress on cognitive function of patients with breast cancer undergoing chemotherapy: a multiple mediation analysis.
     Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07641.
     PubMed     Abstract available
     
     
     
129. WOCKEL A, Park-Simon TW, Korfel A, Raab K, et al
     Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany.
     Breast Cancer Res Treat. 2025 Feb 20. doi: 10.1007/s10549-025-07622.
     PubMed     Abstract available
     
     
     
130. REAM M, Plotke R, Taub CJ, Borowsky PA, et al
     Cognitive behavioral stress management effects on cancer-related distress and neuroendocrine signaling in breast cancer: differential effects by neighborhood disadvantage.
     Breast Cancer Res Treat. 2025 Feb 18. doi: 10.1007/s10549-025-07631.
     PubMed     Abstract available
     
     
     
131. DESAI R, Jain A
     Long-term benefits of exercise interventions during chemotherapy in breast cancer: insights from the optitrain trial calling for longitudinal studies.
     Breast Cancer Res Treat. 2025 Feb 17. doi: 10.1007/s10549-025-07638.
     PubMed    
     
     
     
132. HOLZEL D, Schlesinger-Raab A, Schubert-Fritschle G, Halfter K, et al
     Prolonged time to breast cancer surgery and the risk of metastasis: an explorative simulation analysis using epidemiological data from Germany and the USA.
     Breast Cancer Res Treat. 2025 Feb 17. doi: 10.1007/s10549-025-07630.
     PubMed     Abstract available
     
     
     
133. HUANG Z, Liu Y, Li S, Li Y, et al
     IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2- breast cancer patients after neoadjuvant chemotherapy.
     Breast Cancer Res Treat. 2025 Feb 15. doi: 10.1007/s10549-025-07645.
     PubMed     Abstract available
     
     
     
134. ALBESHAN SM, Almuqbil MM, Elsharkawi MM, Nassri H, et al
     Outcomes of the Saudi breast cancer early detection program: a nine-year analysis (2012-2020).
     Breast Cancer Res Treat. 2025 Feb 14. doi: 10.1007/s10549-025-07633.
     PubMed     Abstract available
     
     
     
135. DAI YW, Wu ZX, Cheng Y, Wu HD, et al
     Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages.
     Breast Cancer Res Treat. 2025 Feb 14. doi: 10.1007/s10549-025-07623.
     PubMed     Abstract available
     
     
     
136. SUBELACK J, Morant R, Blum M, Eichenberger A, et al
     Risk factors for interval breast cancer: insights from a decade of a mammography screening program.
     Breast Cancer Res Treat. 2025 Feb 12. doi: 10.1007/s10549-025-07619.
     PubMed     Abstract available
     
     
     
137. FENG X, Deng Z, McCullough MS, May BJ, et al
     The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors.
     Breast Cancer Res Treat. 2025 Feb 10. doi: 10.1007/s10549-025-07611.
     PubMed     Abstract available
     
     
     
138. CHEN N, Matossian M, Saha P, Rampurwala M, et al
     A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
     Breast Cancer Res Treat. 2025 Feb 10. doi: 10.1007/s10549-025-07626.
     PubMed     Abstract available
     
     
     
139. MAYER EL, Smith ML, Guerin A, Latremouille-Viau D, et al
     Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.
     Breast Cancer Res Treat. 2025 Feb 7. doi: 10.1007/s10549-025-07627.
     PubMed     Abstract available
     
     
     
140. JOGENDRAN M, Flemming JA, Djerboua M, Korzeniowski M, et al
     The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study.
     Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07612.
     PubMed     Abstract available
     
     
     
141. COOPER K, Nalbant G, Essat M, Harnan S, et al
     Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.
     Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-024-07596.
     PubMed     Abstract available
     
     
     
142. JANSEN BAM, Bargon CA, Bouman MA, van der Molen DRM, et al
     Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy-results of the multicenter UMBRELLA breast cancer cohort.
     Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07613.
     PubMed     Abstract available
     
     
     
143. BONADIO RC, Tavares MC, Balint FC, de Sousa IM, et al
     Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.
     Breast Cancer Res Treat. 2025 Feb 3. doi: 10.1007/s10549-025-07628.
     PubMed     Abstract available
     
     
     
144. PARK E, Peterson L, McKeon S, Fiala MA, et al
     Returning to work after breast cancer: a longitudinal analysis of employment and financial hardship.
     Breast Cancer Res Treat. 2025 Feb 2. doi: 10.1007/s10549-025-07624.
     PubMed     Abstract available
     
     
     
145. HASHEMI MH, Moaiery H, Nikkhoo B, Zamani F, et al
     Molecular Dynamics of Breast Cancer Subtypes: The Role of FAM83H-AS1 Long Non-coding RNA in Breast Cancer Metastasis.
     Breast Cancer Res Treat. 2025 Feb 1. doi: 10.1007/s10549-024-07603.
     PubMed     Abstract available
     
     
     
146. ERGAS IJ, Cheng RK, Roh JM, Kresovich JK, et al
     Diet quality and cardiometabolic health in breast cancer survivors: the Pathways Study.
     Breast Cancer Res Treat. 2025 Feb 1. doi: 10.1007/s10549-025-07629.
     PubMed     Abstract available
     
     
     
147. NEUNER JM, Stolley M, Kamaraju S, Tiegs J, et al
     The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence.
     Breast Cancer Res Treat. 2025;209:541-552.
     PubMed     Abstract available
     
     
     
148. LONG R, Luo Y, Cao M, Cao K, et al
     Malignancy risk stratification prediction of BI-RADS 4B calcifications based on contrast-enhanced mammographic features: a multicenter study.
     Breast Cancer Res Treat. 2025;210:135-145.
     PubMed     Abstract available
     
     
     
149. LEE CW, Shin HJ, Kim HJ, Baek S, et al
     Performance of high-resolution diffusion-weighted magnetic resonance imaging for detecting clinically occult early breast cancers: a multi-reader study.
     Breast Cancer Res Treat. 2025;210:71-86.
     PubMed     Abstract available
     
     
     
150. SAKATANI T, Tsuda H, Yoshida M, Honma N, et al
     Current status and challenges in HER2 IHC assessment: scoring survey results in Japan.
     Breast Cancer Res Treat. 2025;210:27-36.
     PubMed     Abstract available
     
     
     
151. KUO MC, Sims J, Solis OK, Meszoely IM, et al
     Disease recurrence in patients undergoing mastectomy for ductal carcinoma in situ.
     Breast Cancer Res Treat. 2025;209:675-679.
     PubMed     Abstract available
     
     
     
152. CHIKARMANE SA, Gibson A, Chesebro AL, Giess CS, et al
     Frequency and outcomes of new or suspicious MRI findings on breast MRI for patients on neoadjuvant therapy.
     Breast Cancer Res Treat. 2025;209:521-531.
     PubMed     Abstract available
     
     
     January 2025
153. LIU G, Pan LZ, Chen J, Ma J, et al
     Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms.
     Breast Cancer Res Treat. 2025 Jan 28. doi: 10.1007/s10549-025-07620.
     PubMed     Abstract available
     
     
     
154. STEARNS V, Chen R, Blackford AL, Saylor E, et al
     The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer.
     Breast Cancer Res Treat. 2025 Jan 27. doi: 10.1007/s10549-024-07591.
     PubMed     Abstract available
     
     
     
155. FEFFERMAN ML, Chan K, Cotler J, Thompson DM, et al
     Did the COVID-19 consortium recommendations impact the treatment of breast cancer during the COVID-19 pandemic?
     Breast Cancer Res Treat. 2025 Jan 26. doi: 10.1007/s10549-025-07617.
     PubMed     Abstract available
     
     
     
156. DOYLE C, Lohmann AE, Iqbal N, Henning JW, et al
     A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy +/- targeted therapy in HR + HER2-negative advanced br
     Breast Cancer Res Treat. 2025 Jan 23. doi: 10.1007/s10549-024-07580.
     PubMed     Abstract available
     
     
     
157. KAI C, Tamori H, Ohtsuka T, Nara M, et al
     Classifying the molecular subtype of breast cancer using vision transformer and convolutional neural network features.
     Breast Cancer Res Treat. 2025 Jan 22. doi: 10.1007/s10549-025-07614.
     PubMed     Abstract available
     
     
     
158. WILLIAMSON J, Kelley K, Scholand MB, Crossno C, et al
     Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan.
     Breast Cancer Res Treat. 2025 Jan 22. doi: 10.1007/s10549-024-07586.
     PubMed     Abstract available
     
     
     
159. ISIK B, Davey MG, Jaffer AA, Buckley J, et al
     Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.
     Breast Cancer Res Treat. 2025 Jan 20. doi: 10.1007/s10549-025-07615.
     PubMed     Abstract available
     
     
     
160. ROHAN TE, Wang Y, Couch F, Feigelson HS, et al
     Clinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.
     Breast Cancer Res Treat. 2025 Jan 20. doi: 10.1007/s10549-024-07599.
     PubMed     Abstract available
     
     
     
161. ASHOK KUMAR P, Sampat P, Sandhu M, Kumar VCS, et al
     A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel.
     Breast Cancer Res Treat. 2025 Jan 19. doi: 10.1007/s10549-024-07597.
     PubMed     Abstract available
     
     
     
162. BASHEY SZ, Kordon A, Ositelu K, Rao A, et al
     The role of statins in breast cancer survivors.
     Breast Cancer Res Treat. 2025 Jan 16. doi: 10.1007/s10549-024-07605.
     PubMed     Abstract available
     
     
     
163. BOGACZ P, Pelc Z, Mlak R, Sedlak K, et al
     Sentinel lymph node biopsy in breast cancer: the role of ICG fluorescence after neoadjuvant chemotherapy.
     Breast Cancer Res Treat. 2025 Jan 14. doi: 10.1007/s10549-025-07608.
     PubMed     Abstract available
     
     
     
164. NYQVIST-STRENG J, Helou M, Helou K, Chamalidou C, et al
     The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.
     Breast Cancer Res Treat. 2025 Jan 12. doi: 10.1007/s10549-025-07610.
     PubMed     Abstract available
     
     
     
165. MANIRUZZAMAN M, Bhuiyan MRH, Jaman MS, Haque MS, et al
     MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application.
     Breast Cancer Res Treat. 2025 Jan 10. doi: 10.1007/s10549-024-07600.
     PubMed     Abstract available
     
     
     
166. GOKSEN TOSUN N, Kaplan O
     Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263.
     Breast Cancer Res Treat. 2025 Jan 9. doi: 10.1007/s10549-024-07587.
     PubMed     Abstract available
     
     
     
167. SCAFETTA R, Zagami P, Del Re M, Criscitiello C, et al
     Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences.
     Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07595.
     PubMed     Abstract available
     
     
     
168. VICINI E, Galimberti V, Leonardi MC, Kahler-Ribeiro-Fontana S, et al
     Shifting from axillary dissection to targeted axillary surgery after neoadjuvant treatment: the evolving management of occult breast cancer in a monoinstitutional series of 114 patients.
     Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07604.
     PubMed     Abstract available
     
     
     
169. SILVA CR, Vieira DP, de Freitas AZ, Ribeiro MS, et al
     Photodynamic therapy as a strategic ally in radiotherapy for triple-negative breast cancer: the importance of treatment order.
     Breast Cancer Res Treat. 2025 Jan 8. doi: 10.1007/s10549-024-07607.
     PubMed     Abstract available
     
     
     
170. OSLER TS, Schoeman M, Pretorius WJS, Mathew CG, et al
     Application of genetic testing criteria for hereditary breast cancer in South Africa.
     Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07585.
     PubMed     Abstract available
     
     
     
171. SANOBA SA, Thull DL, McAuliffe PF, Steiman JG, et al
     Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
     Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07573.
     PubMed    
     
     
     
172. PILEHVARI A, You W, Kimmick G, Bonilla G, et al
     Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.
     Breast Cancer Res Treat. 2025 Jan 7. doi: 10.1007/s10549-024-07593.
     PubMed     Abstract available
     
     
     
173. KNOWLTON SE, Wardell AC, Bailey C, Connelly B, et al
     Assessment of the functional and health-related needs of patients with metastatic breast cancer prior to initiation of cancer treatment.
     Breast Cancer Res Treat. 2025 Jan 6. doi: 10.1007/s10549-024-07590.
     PubMed     Abstract available
     
     
     
174. JUNG W, Park SH, Park YM, Song YM, et al
     Weight change and cardiovascular disease incidence in breast cancer survivors: a nationwide cohort study.
     Breast Cancer Res Treat. 2025 Jan 6. doi: 10.1007/s10549-024-07594.
     PubMed     Abstract available
     
     
     
175. XU Y, Cai Q, Li J, Guo W, et al
     Frequency of somatic and germline variants of predisposition genes in young Chinese women with breast cancer.
     Breast Cancer Res Treat. 2025 Jan 5. doi: 10.1007/s10549-024-07602.
     PubMed     Abstract available
     
     
     
176. MARK C, Pujara V, Boyle MK, Yuan Y, et al
     Demographic and clinical trends of young breast cancer patients from the national cancer database: disproportionate effect on minority populations.
     Breast Cancer Res Treat. 2025 Jan 5. doi: 10.1007/s10549-024-07588.
     PubMed     Abstract available
     
     
     
177. AHMED GA, Baron DH, Agrawal A
     Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis.
     Breast Cancer Res Treat. 2025;209:229-252.
     PubMed     Abstract available
     
     
     
178. LI JJX, Ng JKM, Hon NKY, See KW, et al
     Effects on lymph node size, staging and primary tumor histology on diagnostic accuracy of axillary lymph node aspirate of breast cancers.
     Breast Cancer Res Treat. 2025;209:15-20.
     PubMed     Abstract available
     
     
     
179. SAMAHA M, Fellner A, Raque K, Kuritzky A, et al
     Magnetic lymphatic tracing for omission of sentinel lymph node biopsies in mastectomy patients: a community cancer center experience.
     Breast Cancer Res Treat. 2025;209:161-166.
     PubMed     Abstract available
     
     
     
180. SITU J, Walker C, Jayathungage Don TD, Suami H, et al
     Discordance between peritumoral and subareolar injections for mapping sentinel lymph nodes in the breast.
     Breast Cancer Res Treat. 2025;209:283-290.
     PubMed     Abstract available
     
     
     
181. ROSENBERGER LH, Thomas SM, Hieken TJ, Gallagher KK, et al
     Germline genetic mutations in a multi-center cohort of 248 phyllodes tumors.
     Breast Cancer Res Treat. 2025;209:275-282.
     PubMed     Abstract available
     
     
     
182. SHIN E, Kim HM, Koo JS
     CD68 positive and/or CD163 positive tumor-associated macrophages and PD-L1 expression in breast phyllodes tumor.
     Breast Cancer Res Treat. 2025;209:261-273.
     PubMed     Abstract available
     
     
     December 2024
183. FALTINOVA M, Vehmanen L, Lyytinen H, Savolainen-Peltonen H, et al
     Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial.
     Breast Cancer Res Treat. 2024 Dec 27. doi: 10.1007/s10549-024-07564.
     PubMed     Abstract available
     
     
     
184. MALON D, Molto C, Prasla S, Cuthbert D, et al
     Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor.
     Breast Cancer Res Treat. 2024 Dec 25. doi: 10.1007/s10549-024-07578.
     PubMed     Abstract available
     
     
     
185. LAMONT EB, Stein E, Tarantino P, Tolaney SM, et al
     Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy.
     Breast Cancer Res Treat. 2024 Dec 20. doi: 10.1007/s10549-024-07581.
     PubMed     Abstract available
     
     
     
186. LEGGAT-BARR K, Yee D, Duralde E, Hodge C, et al
     Correction: A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
     Breast Cancer Res Treat. 2024 Dec 20. doi: 10.1007/s10549-024-07572.
     PubMed    
     
     
     
187. YUE M, Zhao J, Wu S, Cai L, et al
     Establishment of multiple machine learning prognostic model for gene differences between primary tumors and lymph nodes in luminal breast cancer.
     Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07574.
     PubMed     Abstract available
     
     
     
188. SIGURJONSDOTTIR G, De Marchi T, Ehinger A, Hartman J, et al
     Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort.
     Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07561.
     PubMed     Abstract available
     
     
     
189. KAPPOS EA, Fabi A, Halbeisen FS, Abu-Ghazaleh A, et al
     Vascularized lymph node transfer (VLNT) versus lymphaticovenous anastomosis (LVA) for chronic breast cancer-related lymphedema (BCRL): a retrospective cohort study of effectiveness over time.
     Breast Cancer Res Treat. 2024 Dec 10. doi: 10.1007/s10549-024-07567.
     PubMed     Abstract available
     
     
     
190. BHATTACHARYA M, Liu B, Kurian AW, Stevens J, et al
     Receipt of guideline-concordant care and survival among young adult women with non-metastatic breast cancer.
     Breast Cancer Res Treat. 2024 Dec 9. doi: 10.1007/s10549-024-07570.
     PubMed     Abstract available
     
     
     
191. WU M, Huang Q, Zhang L, Liu Y, et al
     Apo10 and TKTL1 in blood macrophages as potential biomarkers for early diagnosis of operable breast cancer.
     Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07569.
     PubMed     Abstract available
     
     
     
192. PRASATH V, Boutrid H, Wesolowski R, Abdel-Rasoul M, et al
     Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
     Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07551.
     PubMed     Abstract available
     
     
     
193. DI LEONE A, Filippone A, Maggiore C, Rossi MM, et al
     The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study.
     Breast Cancer Res Treat. 2024 Dec 4. doi: 10.1007/s10549-024-07553.
     PubMed     Abstract available
     
     
     
194. RUGO HS, Campbell M, Yau C, Jo Chien A, et al
     Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
     Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555.
     PubMed     Abstract available
     
     
     
195. LEONE JP, Leone J, Hassett MJ, Freedman RA, et al
     Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study.
     Breast Cancer Res Treat. 2024 Dec 2. doi: 10.1007/s10549-024-07562.
     PubMed     Abstract available
     
     
     
196. SCHRUP S, Hardway H, Vierkant RA, Winham SJ, et al
     Microcalcifications in benign breast biopsies: association with lesion type and risk.
     Breast Cancer Res Treat. 2024;208:543-551.
     PubMed     Abstract available
     
     
     
197. BOWLES EJA, Ramin C, Vo JB, Feigelson HS, et al
     Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018.
     Breast Cancer Res Treat. 2024;208:577-587.
     PubMed     Abstract available
     
     
     
198. FALADE IO, Switalla KM, Baxter ME, Quirarte A, et al
     Variation in surgical treatment by body mass index in patients with invasive lobular carcinoma of the breast.
     Breast Cancer Res Treat. 2024;208:569-575.
     PubMed     Abstract available
     
     
     
199. BEYPINAR I, Demir H, Yaslikaya S, Koseci T, et al
     Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.
     Breast Cancer Res Treat. 2024;208:597-604.
     PubMed     Abstract available
     
     
     
200. LAITMAN Y, Niskakoski A, Bernstein-Molho R, Koskinen L, et al
     Phenotypes of carriers of two mutated alleles in major cancer susceptibility genes.
     Breast Cancer Res Treat. 2024;208:589-595.
     PubMed     Abstract available
     
     
     
201. KUO AM, Reingold RE, Ketosugbo KF, Pan A, et al
     Oral minoxidil for late alopecia in cancer survivors.
     Breast Cancer Res Treat. 2024;208:491-499.
     PubMed     Abstract available
     
     
     
202. SOLIS O, Addae J, Sweeting R, Meszoely I, et al
     Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in patients with ductal carcinoma in situ.
     Breast Cancer Res Treat. 2024;208:565-568.
     PubMed     Abstract available
     
     
     November 2024
203. ROZENBLIT M, Qing T, Ye Y, Zhao H, et al
     Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history.
     Breast Cancer Res Treat. 2024 Nov 27. doi: 10.1007/s10549-024-07560.
     PubMed     Abstract available
     
     
     
204. ANAMPA JD, Alvarez Soto A, Bernal AM, Acuna-Villaorduna A, et al
     Racial disparities in treatment and outcomes between Hispanic and non-Hispanic black women with triple-negative breast cancer.
     Breast Cancer Res Treat. 2024 Nov 26. doi: 10.1007/s10549-024-07565.
     PubMed     Abstract available
     
     
     
205. HANF D, Fasching P, Gass P, Matthias W Beckmann, et al
     Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers.
     Breast Cancer Res Treat. 2024 Nov 26. doi: 10.1007/s10549-024-07545.
     PubMed     Abstract available
     
     
     
206. ROCQUE GB, Blum JL, Ji Y, Pluard T, et al
     Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.
     Breast Cancer Res Treat. 2024 Nov 25. doi: 10.1007/s10549-024-07524.
     PubMed     Abstract available
     
     
     
207. LACZMANSKA I, Matkowski R, Supplitt S, Karpinski P, et al
     Correction: Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.
     Breast Cancer Res Treat. 2024 Nov 23. doi: 10.1007/s10549-024-07544.
     PubMed    
     
     
     
208. MATOSSIAN MD, Shiang C, Dolcen DN, Dreyer M, et al
     High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.
     Breast Cancer Res Treat. 2024 Nov 23. doi: 10.1007/s10549-024-07515.
     PubMed     Abstract available
     
     
     
209. LONNING PE, Nikolaienko O, Knappskog S
     Letter to the Editor in response to paper "BRCA1 promoter methylation in triple-negative breast cancer......" by K Daster et al.
     Breast Cancer Res Treat. 2024 Nov 22. doi: 10.1007/s10549-024-07563.
     PubMed    
     
     
     
210. ZHAO H, Shen C, Laureano JJ, Lei X, et al
     Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021.
     Breast Cancer Res Treat. 2024 Nov 22. doi: 10.1007/s10549-024-07552.
     PubMed     Abstract available
     
     
     
211. REFAAT S, Al-Rashidi HE, El Azeem RAA, Nouh WE, et al
     The functional TNF-alpha(-308)G > a single-nucleotide polymorphism (rs1800629): association with the predictive indices of breast cancer carcinogenesis.
     Breast Cancer Res Treat. 2024 Nov 21. doi: 10.1007/s10549-024-07536.
     PubMed     Abstract available
     
     
     
212. ENGEL J, Wieder V, Bauer M, Kaufhold S, et al
     Correction: Prognostic and predictive impact of NOTCH1 in early breast cancer.
     Breast Cancer Res Treat. 2024 Nov 20. doi: 10.1007/s10549-024-07520.
     PubMed    
     
     
     
213. VAIDYA R, Till C, Henry NL, Fisch MJ, et al
     Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer.
     Breast Cancer Res Treat. 2024 Nov 19. doi: 10.1007/s10549-024-07523.
     PubMed     Abstract available
     
     
     
214. GOLDVASER H, Yerushalmi R, Mutai R, Kuchuk I, et al
     ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.
     Breast Cancer Res Treat. 2024 Nov 19. doi: 10.1007/s10549-024-07549.
     PubMed     Abstract available
     
     
     
215. BETTARIGA F, Taaffe DR, Crespo-Garcia C, Clay TD, et al
     Effects of resistance training vs high intensity interval training on body composition, muscle strength, cardiorespiratory fitness, and quality of life in survivors of breast cancer: a randomized trial.
     Breast Cancer Res Treat. 2024 Nov 18. doi: 10.1007/s10549-024-07559.
     PubMed     Abstract available
     
     
     
216. LEE AW, Solis C, Tubman S, Wells N, et al
     Factors associated with breast cancer detection method in California women: an analysis of California Health Interview Survey data.
     Breast Cancer Res Treat. 2024 Nov 16. doi: 10.1007/s10549-024-07534.
     PubMed     Abstract available
     
     
     
217. KO G, Li Q, Liu N, Amir E, et al
     Impact of the COVID-19 pandemic on breast cancer surgeries in a Canadian population.
     Breast Cancer Res Treat. 2024 Nov 15. doi: 10.1007/s10549-024-07547.
     PubMed     Abstract available
     
     
     
218. ONASANYA O, Rosenblatt P, dosReis S, Onukwugha E, et al
     Trajectories of antidepressant use after tamoxifen initiation among young and middle-aged women with breast cancer.
     Breast Cancer Res Treat. 2024 Nov 15. doi: 10.1007/s10549-024-07554.
     PubMed     Abstract available
     
     
     
219. RELLA R, Belli P, Romanucci G, Bufi E, et al
     Association between mammographic breast density and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
     Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07548.
     PubMed     Abstract available
     
     
     
220. LEGGAT-BARR K, Yee D, Duralde E, Hodge C, et al
     A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
     Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07522.
     PubMed     Abstract available
     
     
     
221. RIZK M, Mokbel K
     Enhancing surgical precision: active marker localization at the time of biopsy in breast cancer management.
     Breast Cancer Res Treat. 2024 Nov 12. doi: 10.1007/s10549-024-07550.
     PubMed    
     
     
     
222. HO KL, Tu Y, Dibble KE, Visvanathan K, et al
     The food environment and postdiagnosis weight gain among Black women breast cancer survivors in Maryland.
     Breast Cancer Res Treat. 2024 Nov 10. doi: 10.1007/s10549-024-07543.
     PubMed     Abstract available
     
     
     
223. KOMATSU N, Chishima T, Watanabe C, Taruno K, et al
     Correction: Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data.
     Breast Cancer Res Treat. 2024 Nov 9. doi: 10.1007/s10549-024-07521.
     PubMed    
     
     
     
224. EE C, Singleton A, Elder E, Davis N, et al
     The experience of weight gain during and after breast cancer treatment: a qualitative study.
     Breast Cancer Res Treat. 2024 Nov 7. doi: 10.1007/s10549-024-07528.
     PubMed     Abstract available
     
     
     
225. ALMEKINDERS CAM, Lin L, Beijnen JH, Sonke GS, et al
     Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort.
     Breast Cancer Res Treat. 2024 Nov 7. doi: 10.1007/s10549-024-07542.
     PubMed     Abstract available
     
     
     
226. PISLAR N, Gasljevic G, Matos E, Pilko G, et al
     Predicting nodal response to neoadjuvant treatment in breast cancer with core biopsy biomarkers of tumor microenvironment using data mining.
     Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07539.
     PubMed     Abstract available
     
     
     
227. VADLAKONDA A, Chervu NL, Porter G, Sakowitz S, et al
     Racial disparities in presenting stage and surgical management among octogenarians with breast cancer: a national cancer database analysis.
     Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07531.
     PubMed     Abstract available
     
     
     
228. XING N, Liu D, Chen L, Wang G, et al
     Quantitative analysis of pressure levels in manual lymphatic drainage across stages of breast cancer-related lymphedema: implications for optimized treatment protocols.
     Breast Cancer Res Treat. 2024 Nov 4. doi: 10.1007/s10549-024-07540.
     PubMed     Abstract available
     
     
     
229. CHIEN YN, Lin LY, Lin YC, Hsieh YC, et al
     Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019.
     Breast Cancer Res Treat. 2024 Nov 2. doi: 10.1007/s10549-024-07527.
     PubMed     Abstract available
     
     
     
230. PASETTO CV, Aguiar FN, Peixoto MB, Doria MT, et al
     Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.
     Breast Cancer Res Treat. 2024;208:9-18.
     PubMed     Abstract available
     
     
     
231. BORREGO MR, Lu YS, Reyes-Cosmelli F, Park YH, et al
     SGLT2 inhibition improves PI3Kalpha inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.
     Breast Cancer Res Treat. 2024;208:111-121.
     PubMed     Abstract available
     
     
     
232. BOURGEOIS P
     Letter to the BRCT editor.
     Breast Cancer Res Treat. 2024;208:201.
     PubMed    
     
     
     
233. PEIPINS LA, Dasari S, Viox MH, Rodriguez JL, et al
     Information needs persist after genetic counseling and testing for BRCA1/2 and Lynch Syndrome.
     Breast Cancer Res Treat. 2024;208:19-27.
     PubMed     Abstract available
     
     
     
234. CHEN Q, Campbell I, Elwood M, Cavadino A, et al
     Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis.
     Breast Cancer Res Treat. 2024;208:237-251.
     PubMed     Abstract available
     
     
     
235. RAMPAL R, Jones SJ, Hartup S, Robertson C, et al
     Three and twelve-month analysis of the PROM-Q study: comparison of patient-reported outcome measures using the BREAST-Q questionnaire in pre- vs. sub-pectoral implant-based immediate breast reconstruction.
     Breast Cancer Res Treat. 2024;208:275-282.
     PubMed     Abstract available
     
     
     
236. KAIDAR-PERSON O, Faermann R, Polikar D, Cohen K, et al
     A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction.
     Breast Cancer Res Treat. 2024;208:359-367.
     PubMed     Abstract available
     
     
     
237. CHO Y, Park EK, Chang Y, Kwon MR, et al
     Concordant and discordant breast density patterns by different approaches for assessing breast density and breast cancer risk.
     Breast Cancer Res Treat. 2024 Nov 1. doi: 10.1007/s10549-024-07541.
     PubMed     Abstract available
     
     
     October 2024
238. TERRA L, Boekel NB, Hooning MH, Collee M, et al
     Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.
     Breast Cancer Res Treat. 2024 Oct 31. doi: 10.1007/s10549-024-07516.
     PubMed     Abstract available
     
     
     
239. OZA S, Patil S, Sampathkumar Y, Gany F, et al
     Trends in exercise initiation and participation among employed breast cancer survivors undergoing curative treatment.
     Breast Cancer Res Treat. 2024 Oct 31. doi: 10.1007/s10549-024-07526.
     PubMed     Abstract available
     
     
     
240. BOSCOLO BIELO L, Guerini Rocco E, Crimini E, Repetto M, et al
     Molecular tumor board in patients with metastatic breast cancer.
     Breast Cancer Res Treat. 2024 Oct 30. doi: 10.1007/s10549-024-07535.
     PubMed     Abstract available
     
     
     
241. VAZ-GONCALVES L, Protani MM, Saunus JM, Colditz GA, et al
     Continental differences in the association between excess body weight and prognosis in triple-negative breast cancer: a meta-analysis.
     Breast Cancer Res Treat. 2024 Oct 30. doi: 10.1007/s10549-024-07538.
     PubMed     Abstract available
     
     
     
242. GONZALEZ-NUNEZ C, Mohar A, Reynoso-Noveron N, Alvarez-Gomez RM, et al
     Clinical characteristics of male patients with breast cancer in the Latino population.
     Breast Cancer Res Treat. 2024 Oct 29. doi: 10.1007/s10549-024-07525.
     PubMed     Abstract available
     
     
     
243. TAYA M, Merenbakh-Lamin K, Zubkov A, Honig Z, et al
     Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer.
     Breast Cancer Res Treat. 2024 Oct 29. doi: 10.1007/s10549-024-07507.
     PubMed     Abstract available
     
     
     
244. PHUNG TH, Pham TT, Nguyen HT, Nguyen DT, et al
     Clinicopathological characteristics of mucinous breast cancer: a retrospective analysis of a 6-years study from national cancer center in Vietnam.
     Breast Cancer Res Treat. 2024 Oct 23. doi: 10.1007/s10549-024-07529.
     PubMed     Abstract available
     
     
     
245. JAHANGIRI S, Abdan Z, Soroush A, Houshmand M, et al
     Strong association of single nucleotide polymorphisms in BRCA1, ATM, and CHEK2 with breast cancer susceptibility in a sub-population of Iranian women.
     Breast Cancer Res Treat. 2024 Oct 22. doi: 10.1007/s10549-024-07503.
     PubMed     Abstract available
     
     
     
246. WOLFRAM S, Herriman SA, Lipps DB
     Prevalence and mechanisms of subacromial impingement in breast cancer patients after breast-conserving surgery and radiation therapy: a case-cohort study.
     Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07514.
     PubMed     Abstract available
     
     
     
247. ROSENBERG SM, Zheng Y, Santos K, Riley E, et al
     Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer.
     Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07510.
     PubMed     Abstract available
     
     
     
248. STEARNS V, ONeill A, Schneider BP, Skaar TC, et al
     CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
     Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07519.
     PubMed     Abstract available
     
     
     
249. COTTU P, Cheeseman S, Hall P, Wockel A, et al
     Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.
     Breast Cancer Res Treat. 2024 Oct 20. doi: 10.1007/s10549-024-07506.
     PubMed     Abstract available
     
     
     
250. GARCIA-MURILLAS I, Cutts RJ, Walsh-Crestani G, Phillips E, et al
     Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer.
     Breast Cancer Res Treat. 2024 Oct 18. doi: 10.1007/s10549-024-07508.
     PubMed     Abstract available
     
     
     
251. TALEC H, Aube C, Guerin-Charbonnel C, Berge P, et al
     The use of a clip prior to neoadjuvant chemotherapy for breast cancer with microcalcifications may not always be required.
     Breast Cancer Res Treat. 2024 Oct 17. doi: 10.1007/s10549-024-07517.
     PubMed     Abstract available
     
     
     
252. ITO M, Amari M, Sato A, Hikichi M, et al
     Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy.
     Breast Cancer Res Treat. 2024 Oct 17. doi: 10.1007/s10549-024-07509.
     PubMed     Abstract available
     
     
     
253. BRUNELLE CL, Serig A
     Is axillary web syndrome a risk factor for breast cancer-related lymphedema of the upper extremity? A systematic review and meta-analysis.
     Breast Cancer Res Treat. 2024 Oct 16. doi: 10.1007/s10549-024-07518.
     PubMed     Abstract available
     
     
     
254. LAI SW
     Comment on "Association between prediabetes and breast cancer: a comprehensive meta-analysis".
     Breast Cancer Res Treat. 2024 Oct 15. doi: 10.1007/s10549-024-07505.
     PubMed    
     
     
     
255. ISHIKAWA E, Watanabe T, Kihara T, Kuroiwa M, et al
     The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer.
     Breast Cancer Res Treat. 2024 Oct 14. doi: 10.1007/s10549-024-07492.
     PubMed     Abstract available
     
     
     
256. LV Z, Wang TY, Bi Y, Li D, et al
     BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses.
     Breast Cancer Res Treat. 2024 Oct 14. doi: 10.1007/s10549-024-07504.
     PubMed     Abstract available
     
     
     
257. LABELLA M, Lile-King RE, Agala CB, Spanheimer PM, et al
     Trends in management and related outcomes for occult primary breast cancer.
     Breast Cancer Res Treat. 2024 Oct 13. doi: 10.1007/s10549-024-07500.
     PubMed     Abstract available
     
     
     
258. DE AMORIM ISS, Pinheiro D, da Silva Oliveira M, de Sousa Rodrigues MM, et al
     APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis.
     Breast Cancer Res Treat. 2024 Oct 13. doi: 10.1007/s10549-024-07512.
     PubMed     Abstract available
     
     
     
259. DASTER K, Hench J, Diepenbruck M, Volkmann K, et al
     BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors.
     Breast Cancer Res Treat. 2024 Oct 11. doi: 10.1007/s10549-024-07502.
     PubMed     Abstract available
     
     
     
260. PACHUAU L, Lalremmawia H, Ralte L, Vanlalpeka J, et al
     Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe.
     Breast Cancer Res Treat. 2024 Oct 9. doi: 10.1007/s10549-024-07501.
     PubMed     Abstract available
     
     
     
261. RASHID NS, Lamba N, Catalano PJ, Bi WL, et al
     Intracranial outcomes following neurosurgical resection in patients with brain metastases secondary to HER2-positive breast cancer versus other subtypes.
     Breast Cancer Res Treat. 2024 Oct 5. doi: 10.1007/s10549-024-07493.
     PubMed     Abstract available
     
     
     
262. BITSIE KR, Pearson TA, Kwan ML, Yaghjyan L, et al
     Race and ethnicity and self-reported racial/ethnic discrimination in breast cancer patient interactions with providers in the Pathways Study.
     Breast Cancer Res Treat. 2024 Oct 5. doi: 10.1007/s10549-024-07499.
     PubMed     Abstract available
     
     
     
263. BROWNE IM, McLaughlin RA, Weadick CS, O'Sullivan S, et al
     Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX(R) testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
     Breast Cancer Res Treat. 2024 Oct 4. doi: 10.1007/s10549-024-07486.
     PubMed     Abstract available
     
     
     
264. KOMATSU N, Chishima T, Watanabe C, Taruno K, et al
     Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer registry data.
     Breast Cancer Res Treat. 2024 Oct 2. doi: 10.1007/s10549-024-07485.
     PubMed     Abstract available
     
     
     
265. KESSLER AJ, Patel R, Gallagher EJ, Sheng T, et al
     Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression.
     Breast Cancer Res Treat. 2024;207:529-532.
     PubMed     Abstract available
     
     
     
266. TOMITA S, Yoshitake T, Matsunaga N, de Kerckhove M, et al
     Patient-reported outcomes and quality of life after breast-conserving surgery, mastectomy, and breast reconstruction assessed using the BREAST-Q questionnaire.
     Breast Cancer Res Treat. 2024;207:641-648.
     PubMed     Abstract available
     
     
     
267. RAJAN KK, Nijveldt JJ, Verheijen S, Siesling S, et al
     Adherence to guideline recommendations for follow-up in patients with DCIS at a large teaching hospital in the Netherlands.
     Breast Cancer Res Treat. 2024;207:633-640.
     PubMed     Abstract available
     
     
     
268. FARIA JP, Assumpcao JG, de Oliveira Matos L, Soardi FC, et al
     Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases.
     Breast Cancer Res Treat. 2024;207:615-624.
     PubMed     Abstract available
     
     
     
269. LEONARDIS JM, Momoh AO, Lipps DB
     Choosing breast-conserving therapy or mastectomy and subpectoral implant breast reconstruction: implications for pectoralis major function.
     Breast Cancer Res Treat. 2024;207:569-578.
     PubMed     Abstract available
     
     
     
270. SOLEIMANI T, Euhus D, Sogunro O, Cope L, et al
     De-escalating indications for excision when breast core needle biopsy returns fibroepithelial lesion-not further characterized.
     Breast Cancer Res Treat. 2024;207:561-568.
     PubMed     Abstract available
     
     
     
271. SANTANA VALENCIANO A, Rivas Fidalgo S, Corral Moreno S, Gamero Medina V, et al
     Surgical marker navigation system in breast conserving surgery and excision of non-palpable lesions: first Spanish single-center experience.
     Breast Cancer Res Treat. 2024;207:533-540.
     PubMed     Abstract available
     
     
     
272. MARTINS-BRANCO D, Brandao M, de Azambuja E
     Response to letter "re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: A nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".
     Breast Cancer Res Treat. 2024 Oct 1. doi: 10.1007/s10549-024-07498.
     PubMed    
     
     
     September 2024
273. VERRECK EEF, Kuijer A, van Steenhoven JEC, Volders JH, et al
     70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study.
     Breast Cancer Res Treat. 2024 Sep 30. doi: 10.1007/s10549-024-07496.
     PubMed     Abstract available
     
     
     
274. WOJCIK KM, Wilson OWA, Kamil D, Rajagopal PS, et al
     Clinical and sociodemographic determinants of older breast cancer survivors' reports of receiving advice about exercise.
     Breast Cancer Res Treat. 2024 Sep 30. doi: 10.1007/s10549-024-07460.
     PubMed     Abstract available
     
     
     
275. GUNSTER JLB, van Duijnhoven FH, Scholten AN, Smorenburg CH, et al
     The efficacy of screening with FDG-PET/CT for distant metastases in breast cancer patients scheduled for neoadjuvant systemic therapy.
     Breast Cancer Res Treat. 2024 Sep 26. doi: 10.1007/s10549-024-07478.
     PubMed     Abstract available
     
     
     
276. KULIGINA ES, Romanko AA, Jankevic T, Martianov AS, et al
     HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles.
     Breast Cancer Res Treat. 2024 Sep 21. doi: 10.1007/s10549-024-07497.
     PubMed     Abstract available
     
     
     
277. JACOB S, Christofferson A, Fisch S, Norwood P, et al
     Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
     Breast Cancer Res Treat. 2024 Sep 21. doi: 10.1007/s10549-024-07481.
     PubMed     Abstract available
     
     
     
278. BANSAL R, Adeyelu T, Elliott A, Walker P, et al
     Genomic and transcriptomic landscape of HER2-low breast cancer.
     Breast Cancer Res Treat. 2024 Sep 20. doi: 10.1007/s10549-024-07495.
     PubMed     Abstract available
     
     
     
279. SCHMIDT JA, Hjorth CF, Farkas DK, Damkier P, et al
     Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study.
     Breast Cancer Res Treat. 2024 Sep 20. doi: 10.1007/s10549-024-07474.
     PubMed     Abstract available
     
     
     
280. JANSSEN LM, de Vries BBLP, Janse MHA, van der Wall E, et al
     Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer.
     Breast Cancer Res Treat. 2024 Sep 16. doi: 10.1007/s10549-024-07484.
     PubMed     Abstract available
     
     
     
281. MIRZA L, Steventon L, Roylance R, Hughes C, et al
     Regional differences in neo/adjuvant chemotherapy timing in patients with early-stage triple-negative breast cancer in England.
     Breast Cancer Res Treat. 2024 Sep 16. doi: 10.1007/s10549-024-07480.
     PubMed     Abstract available
     
     
     
282. THAI CHNC, An SJ, Haase CR, Selfridge JM, et al
     Differential prognostic value of residual nodal burden in breast cancer subtypes.
     Breast Cancer Res Treat. 2024 Sep 15. doi: 10.1007/s10549-024-07494.
     PubMed     Abstract available
     
     
     
283. HENNEGHAN AM, Van Dyk KM, Haywood D, Patel M, et al
     Characterizing cancer-related cognitive impairments and impact on quality of life in women with metastatic breast cancer.
     Breast Cancer Res Treat. 2024 Sep 13. doi: 10.1007/s10549-024-07479.
     PubMed     Abstract available
     
     
     
284. ZHU HR, Wei YB, Guo JQ, Liu XF, et al
     Double-negative T cells with a distinct transcriptomic profile are abundant in the peripheral blood of patients with breast cancer.
     Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07477.
     PubMed     Abstract available
     
     
     
285. NELSON RA, Chlebowski RT, Pan K, Rohan TE, et al
     Breast Cancer Risk Assessment Tool (BCRAT) and long-term breast cancer mortality in the Women's Health Initiative.
     Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07470.
     PubMed     Abstract available
     
     
     
286. DUARTE BN, Alem CER, da Silva Cabello AER, Teixeira SRC, et al
     Risk-reducing surgeries for breast cancer in Brazilian patients undergoing multigene germline panel: impact of results on decision making.
     Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07476.
     PubMed     Abstract available
     
     
     
287. SARTOR H, Hagberg O, Hemmingsson O, Lang K, et al
     Breast cancer recurrence in relation to mode of detection: implications on personalized surveillance.
     Breast Cancer Res Treat. 2024 Sep 10. doi: 10.1007/s10549-024-07475.
     PubMed     Abstract available
     
     
     
288. GUO Q, Liu M, Li Y, Sun Q, et al
     Overcoming technical hurdles in mobile health: insights from the Fit2ThriveMB breast cancer study.
     Breast Cancer Res Treat. 2024 Sep 5. doi: 10.1007/s10549-024-07483.
     PubMed    
     
     
     
289. TANG WZ, Deng WX, Liu TH
     Letter to the editor: "Frequency of zoledronate administration in early breast cancer".
     Breast Cancer Res Treat. 2024 Sep 4. doi: 10.1007/s10549-024-07490.
     PubMed    
     
     
     
290. SWEDE H, Ridwan SM, Strandberg J, Salner AL, et al
     Baseline sLAG-3 levels in Caucasian and African-American breast cancer patients.
     Breast Cancer Res Treat. 2024 Sep 4. doi: 10.1007/s10549-024-07455.
     PubMed     Abstract available
     
     
     August 2024
291. WALYELDEEN AA, Sabet S, Anis SE, Stein T, et al
     Correction: FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancer.
     Breast Cancer Res Treat. 2024 Aug 29. doi: 10.1007/s10549-024-07472.
     PubMed    
     
     
     
292. CONLEY CC, Anderson A, Rodriguez JD, Kang H, et al
     Barriers and facilitators to breast cancer screening among high-risk women: a qualitative study.
     Breast Cancer Res Treat. 2024 Aug 27. doi: 10.1007/s10549-024-07471.
     PubMed     Abstract available
     
     
     
293. BRUFSKY A, Kwan ML, Sandin R, Stergiopoulos S, et al
     Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.
     Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07469.
     PubMed     Abstract available
     
     
     
294. GUNASEKHARAN V, Lin HK, Marczyk M, Rios-Hoyo A, et al
     Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer.
     Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07462.
     PubMed     Abstract available
     
     
     
295. DU X, Huang X, Feng X, Shui Y, et al
     The effects of the-optimal-lymph-flow health IT system application on treatment-related high risk lymphedema in breast cancer patients: a randomized controlled trial.
     Breast Cancer Res Treat. 2024 Aug 23. doi: 10.1007/s10549-024-07468.
     PubMed     Abstract available
     
     
     
296. SPENCER JV, Liu J, Deyarmin B, Hu H, et al
     Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV) status.
     Breast Cancer Res Treat. 2024 Aug 22. doi: 10.1007/s10549-024-07459.
     PubMed     Abstract available
     
     
     
297. WILLIS C, Tan CJ, Chhibber A, Watanabe AH, et al
     Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study.
     Breast Cancer Res Treat. 2024 Aug 22. doi: 10.1007/s10549-024-07458.
     PubMed     Abstract available
     
     
     
298. FRANDSEN CLB, Nohr B, Gottschau M, Viuff JH, et al
     Polycystic ovary syndrome and risk of breast cancer in premenopausal and postmenopausal women: a nationwide population-based cohort study.
     Breast Cancer Res Treat. 2024 Aug 21. doi: 10.1007/s10549-024-07467.
     PubMed     Abstract available
     
     
     
299. ENGEL J, Wieder V, Bauer M, Kaufhold S, et al
     Prognostic and predictive impact of NOTCH1 in early breast cancer.
     Breast Cancer Res Treat. 2024 Aug 17. doi: 10.1007/s10549-024-07444.
     PubMed     Abstract available
     
     
     
300. BLANTER J, Baldwin E, Patel R, Sheng T, et al
     Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer.
     Breast Cancer Res Treat. 2024 Aug 17. doi: 10.1007/s10549-024-07461.
     PubMed     Abstract available
     
     
     
301. BHIMANI J, O'Connell K, Persaud S, Blinder V, et al
     The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system.
     Breast Cancer Res Treat. 2024 Aug 16. doi: 10.1007/s10549-024-07433.
     PubMed     Abstract available
     
     
     
302. MELINK Z, Lustberg MB, Schnell PM, Mezzanotte-Sharpe J, et al
     Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial.
     Breast Cancer Res Treat. 2024 Aug 14. doi: 10.1007/s10549-024-07457.
     PubMed     Abstract available
     
     
     
303. KAUR M, Rothschild HT, Mukhtar RA
     Reply to: "Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".
     Breast Cancer Res Treat. 2024 Aug 12. doi: 10.1007/s10549-024-07465.
     PubMed    
     
     
     
304. LI Z, Ye X
     Integrating social work and shared decision-making for equity in metastatic breast cancer care.
     Breast Cancer Res Treat. 2024 Aug 10. doi: 10.1007/s10549-024-07463.
     PubMed    
     
     
     
305. ALTUNDAG K
     Different distant breast cancer metastases might show discordant hormone receptor status in the same patient.
     Breast Cancer Res Treat. 2024 Aug 10. doi: 10.1007/s10549-024-07464.
     PubMed    
     
     
     
306. ZENG F, Heng J, Guo X, Wang Y, et al
     Correction: The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
     Breast Cancer Res Treat. 2024 Aug 8. doi: 10.1007/s10549-024-07424.
     PubMed    
     
     
     
307. WONG HCY, Lee SF, Caini S, Chan AW, et al
     Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis.
     Breast Cancer Res Treat. 2024 Aug 7. doi: 10.1007/s10549-024-07435.
     PubMed     Abstract available
     
     
     
308. WALYELDEEN AA, Sabet S, Anis SE, Stein T, et al
     FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancer.
     Breast Cancer Res Treat. 2024 Aug 7. doi: 10.1007/s10549-024-07447.
     PubMed     Abstract available
     
     
     
309. FREEMAN HD, Burke LC, Humphrey JG, Wilbers AJ, et al
     Fragmentation of care in breast cancer: greater than the sum of its parts.
     Breast Cancer Res Treat. 2024 Aug 3. doi: 10.1007/s10549-024-07442.
     PubMed     Abstract available
     
     
     
310. KINSEY-TROTMAN S, Nguyen A, Edwards S, Swalling A, et al
     Influence of tumour grade on disease survival in male breast cancer patients: a systematic review.
     Breast Cancer Res Treat. 2024 Aug 2. doi: 10.1007/s10549-024-07446.
     PubMed     Abstract available
     
     
     
311. ROCQUE GB, Eltoum N, Caston NE, Williams CP, et al
     A randomized controlled trial of shared decision-making treatment planning process to enhance shared decision-making in patients with MBC.
     Breast Cancer Res Treat. 2024;206:483-493.
     PubMed     Abstract available
     
     
     
312. SURMELI Z
     Letter to the editor: "Body composition measures as a determinant of alpelisib-related toxicity".
     Breast Cancer Res Treat. 2024;206:677.
     PubMed    
     
     
     
313. ROCA NAVARRO MJ, Oliver Goldaracena JM, Garrido Alonso D, Navarro Monforte Y, et al
     Pre-surgical cryoablation in
     Breast Cancer Res Treat. 2024;206:561-573.
     PubMed     Abstract available
     
     
     
314. STEAD TS, Lu CY, Geletzke A, Butler E, et al
     Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy.
     Breast Cancer Res Treat. 2024;206:575-583.
     PubMed     Abstract available
     
     
     
315. ANDERSON SA, Bartow BB, Harada S, Siegal GP, et al
     p53 protein expression patterns associated with TP53 mutations in breast carcinoma.
     Breast Cancer Res Treat. 2024;207:213-222.
     PubMed     Abstract available
     
     
     
316. ZENG A, Houssami N, Noguchi N, Nickel B, et al
     Frequency and characteristics of errors by artificial intelligence (AI) in reading screening mammography: a systematic review.
     Breast Cancer Res Treat. 2024;207:1-13.
     PubMed     Abstract available
     
     
     
317. PAN K, Nelson RA, Chlebowski RT, Piela R, et al
     Ductal carcinoma in situ and cause-specific mortality among younger and older postmenopausal women: the Women's Health Initiative.
     Breast Cancer Res Treat. 2024;207:65-79.
     PubMed     Abstract available
     
     
     
318. THOMPSON CN, Chandler J, Ju T, Tsai J, et al
     Residual cancer burden in two-stage nipple sparing mastectomy after first stage lumpectomy and devascularization of the nipple areolar complex.
     Breast Cancer Res Treat. 2024;207:143-149.
     PubMed     Abstract available
     
     
     
319. DOWLING GP, Keelan S, Cosgrove NS, Daly GR, et al
     Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease.
     Breast Cancer Res Treat. 2024 Aug 1. doi: 10.1007/s10549-024-07431.
     PubMed     Abstract available
     
     
     July 2024
320. AWAN AA, Stober C, Pond GR, Machado I, et al
     A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer.
     Breast Cancer Res Treat. 2024 Jul 31. doi: 10.1007/s10549-024-07443.
     PubMed     Abstract available
     
     
     
321. IZABELA L, Rafal M, Stanislaw S, Pawel K, et al
     Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.
     Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07441.
     PubMed     Abstract available
     
     
     
322. FANSA S, Ghusn W, Tama E, Nicolalde B, et al
     Efficacy of antiobesity medications among breast cancer survivors taking aromatase inhibitors.
     Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07450.
     PubMed     Abstract available
     
     
     
323. MOKHTARPOUR K, Razi S, Rezaei N
     Correction: Ferroptosis as a promising targeted therapy for triple negative breast cancer.
     Breast Cancer Res Treat. 2024 Jul 30. doi: 10.1007/s10549-024-07438.
     PubMed    
     
     
     
324. WANG Z, Lu Y, Han M, Li A, et al
     Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.
     Breast Cancer Res Treat. 2024 Jul 24. doi: 10.1007/s10549-024-07436.
     PubMed     Abstract available
     
     
     
325. ZHOU K, Zhang M, Zhai D, Wang Z, et al
     Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers.
     Breast Cancer Res Treat. 2024 Jul 19. doi: 10.1007/s10549-024-07437.
     PubMed     Abstract available
     
     
     
326. SATO T, Oshi M, Huang JL, Chida K, et al
     CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
     Breast Cancer Res Treat. 2024 Jul 17. doi: 10.1007/s10549-024-07434.
     PubMed     Abstract available
     
     
     
327. PHILLIPS SM, Starikovsky J, Solk P, Desai R, et al
     Feasibility and preliminary effects of the Fit2ThriveMB pilot physical activity promotion intervention on physical activity and patient reported outcomes in individuals with metastatic breast cancer.
     Breast Cancer Res Treat. 2024 Jul 16. doi: 10.1007/s10549-024-07432.
     PubMed     Abstract available
     
     
     
328. BHAVE MA, Quintanilha JCF, Tukachinsky H, Li G, et al
     Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
     Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07427.
     PubMed    
     
     
     
329. FOLDI J, Blenman KRM, Marczyk M, Gunasekharan V, et al
     Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.
     Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07426.
     PubMed     Abstract available
     
     
     
330. SANJAYA A, Ratnawati H, Adhika OA, Rahmatilah FR, et al
     The heterogeneity of breast cancer metastasis: a bioinformatics analysis utilizing single-cell RNA sequencing data.
     Breast Cancer Res Treat. 2024 Jul 11. doi: 10.1007/s10549-024-07428.
     PubMed     Abstract available
     
     
     
331. DU KY, Wu S, Ma X, Liu Y, et al
     Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot s
     Breast Cancer Res Treat. 2024 Jul 11. doi: 10.1007/s10549-024-07430.
     PubMed     Abstract available
     
     
     
332. KUMAR S, Ziegler Y, Plotner BN, Flatt KM, et al
     Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death.
     Breast Cancer Res Treat. 2024 Jul 9. doi: 10.1007/s10549-024-07420.
     PubMed     Abstract available
     
     
     
333. LIANG E, Beshara M, Sheng H, Huang XW, et al
     A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer.
     Breast Cancer Res Treat. 2024 Jul 8. doi: 10.1007/s10549-024-07423.
     PubMed     Abstract available
     
     
     
334. CHIDA K, Oshi M, Roy AM, Sato T, et al
     Enhanced cancer cell proliferation and aggressive phenotype counterbalance in breast cancer with high BRCA1 gene expression.
     Breast Cancer Res Treat. 2024 Jul 7. doi: 10.1007/s10549-024-07421.
     PubMed     Abstract available
     
     
     
335. BRANTLEY KD, Tamimi RM
     The association between infectious agents and breast cancer: a review of the epidemiologic evidence.
     Breast Cancer Res Treat. 2024 Jul 6. doi: 10.1007/s10549-024-07388.
     PubMed     Abstract available
     
     
     
336. MEZZANOTTE-SHARPE J, ONeill A, Mayer IA, Arteaga CL, et al
     A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
     Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07417.
     PubMed     Abstract available
     
     
     
337. CHEN HW, Kuo WH, Lu YS, Chen IC, et al
     Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in breast cancer risk among East Asian women.
     Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07418.
     PubMed     Abstract available
     
     
     
338. SIMMONS R, Kameyama H, Kubota S, Sun Y, et al
     Sustained delivery of celecoxib from nanoparticles embedded in hydrogel injected into the biopsy cavity to prevent biopsy-induced breast cancer metastasis.
     Breast Cancer Res Treat. 2024 Jul 5. doi: 10.1007/s10549-024-07410.
     PubMed     Abstract available
     
     
     
339. FEFFERMAN ML, Stump TK, Thompson D, Simovic S, et al
     Patient-reported observations on medical procedure timeliness (PROMPT) in breast cancer: a qualitative study.
     Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07406.
     PubMed     Abstract available
     
     
     
340. MAGNONI F, Bianchi B, Pagan E, Corso G, et al
     Long-term outcome of invasive pure micropapillary breast cancer compared with invasive mixed micropapillary and invasive ductal breast cancer: a matched retrospective study.
     Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07422.
     PubMed     Abstract available
     
     
     
341. MATHESON J, Elder K, Nickson C, Park A, et al
     Contrast-enhanced mammography for surveillance in women with a personal history of breast cancer.
     Breast Cancer Res Treat. 2024 Jul 4. doi: 10.1007/s10549-024-07419.
     PubMed     Abstract available
     
     
     
342. FANG T, Hu S, Song X, Wang J, et al
     Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways.
     Breast Cancer Res Treat. 2024 Jul 3. doi: 10.1007/s10549-024-07374.
     PubMed     Abstract available
     
     
     
343. OZ O, Irmak Yuzuguldu R, Yazici A, Kocatepe Cavdar D, et al
     The differences between pure and mixed invasive micropapillary breast cancer: the epithelial-mesenchymal transition molecules and prognosis.
     Breast Cancer Res Treat. 2024 Jul 2. doi: 10.1007/s10549-024-07384.
     PubMed     Abstract available
     
     
     
344. LEE M, Woo J, Peak SH, Kim HG, et al
     An exploratory clinical trial of preoperative non-invasive localization before breast-conserving surgery using augmented reality technology.
     Breast Cancer Res Treat. 2024;206:31-44.
     PubMed     Abstract available
     
     
     
345. HONG R, Cao B, Chen D, Wu W, et al
     Multi-omics portrait of ductal carcinoma in situ in young women.
     Breast Cancer Res Treat. 2024;206:105-118.
     PubMed     Abstract available
     
     
     
346. LI S, Lin Y, Liu G, Shao Z, et al
     Unveiling the potential of breast MRI: a game changer for BI-RADS 4A microcalcifications.
     Breast Cancer Res Treat. 2024;206:425-435.
     PubMed     Abstract available
     
     
     
347. HAAS CB, Chen H, Harrison T, Fan S, et al
     Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization.
     Breast Cancer Res Treat. 2024;206:295-305.
     PubMed     Abstract available
     
     
     
348. ASSAD H, Levitin M, Petrucelli N, Manning M, et al
     Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
     Breast Cancer Res Treat. 2024;206:261-272.
     PubMed     Abstract available
     
     
     
349. SHACHAR E, Raphael A, Katz U, Kessner R, et al
     Body composition measures as a determinant of Alpelisib related toxicity.
     Breast Cancer Res Treat. 2024;206:369-376.
     PubMed     Abstract available
     
     
     June 2024
350. LAMMERS SWM, Geurts SME, Hermans KEPE, van Hellemond IEG, et al
     Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.
     Breast Cancer Res Treat. 2024 Jun 28. doi: 10.1007/s10549-024-07411.
     PubMed     Abstract available
     
     
     
351. SHIEN T, Tsuda H, Sasaki K, Mizusawa J, et al
     Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306.
     Breast Cancer Res Treat. 2024 Jun 27. doi: 10.1007/s10549-024-07408.
     PubMed     Abstract available
     
     
     
352. IWAMOTO T, Niikura N, Watanabe K, Takeshita T, et al
     Prognostic value of the 21-Gene Breast Recurrence Score(R) assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
     Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07414.
     PubMed     Abstract available
     
     
     
353. CRONIN M, Lowery A, McInerney V, Wijns W, et al
     Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology assessment and surveillance pathway for breast cancer patients.
     Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07322.
     PubMed     Abstract available
     
     
     
354. KIMMICK G, Pilehvari A, You W, Bonilla G, et al
     First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.
     Breast Cancer Res Treat. 2024 Jun 26. doi: 10.1007/s10549-024-07415.
     PubMed     Abstract available
     
     
     
355. SINGAREEKA RAGHAVENDRA A, Liu D, Shen Y, Barcenas CH, et al
     Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience.
     Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07309.
     PubMed     Abstract available
     
     
     
356. MCCARTHY AM, Ehsan S, Hughes KS, Lehman CD, et al
     Feasibility of risk assessment for breast cancer molecular subtypes.
     Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07404.
     PubMed     Abstract available
     
     
     
357. SELIEM MA, Mohamadin AM, El-Sayed MIK, Ismail Y, et al
     The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients.
     Breast Cancer Res Treat. 2024 Jun 25. doi: 10.1007/s10549-024-07393.
     PubMed     Abstract available
     
     
     
358. ZHANG D, Fang J, Shan J, Xu L, et al
     SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis in breast cancer.
     Breast Cancer Res Treat. 2024 Jun 24. doi: 10.1007/s10549-024-07401.
     PubMed     Abstract available
     
     
     
359. JOHNSTON E, Cowan K, MacKenzie M, Patton S, et al
     Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project.
     Breast Cancer Res Treat. 2024 Jun 24. doi: 10.1007/s10549-024-07413.
     PubMed     Abstract available
     
     
     
360. KALINSKY K, Spring L, Yam C, Bhave MA, et al
     Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
     Breast Cancer Res Treat. 2024 Jun 21. doi: 10.1007/s10549-024-07412.
     PubMed     Abstract available
     
     
     
361. WEN S, Zhang M, Chen J, Hu L, et al
     Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants.
     Breast Cancer Res Treat. 2024 Jun 20. doi: 10.1007/s10549-024-07409.
     PubMed     Abstract available
     
     
     
362. BRAVO EI, Martinez AM, Alva HP, Sancho DR, et al
     Reliability of Magseed(R) marking before neoadjuvant systemic therapy with subsequent contrast-enhanced mammography in patients with non-palpable breast cancer lesions after treatment: the MAGMA study.
     Breast Cancer Res Treat. 2024 Jun 20. doi: 10.1007/s10549-024-07407.
     PubMed     Abstract available
     
     
     
363. TEUFELSBAUER M, Stickler S, Eggerstorfer MT, Hammond DC, et al
     BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436.
     Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07403.
     PubMed     Abstract available
     
     
     
364. RODRIGUEZ-ROJAS K, Cortes-Reynosa P, Torres-Alamilla P, Rodriguez-Ochoa N, et al
     A novel role of IGFBP5 in the migration, invasion and spheroids formation induced by IGF-I and insulin in MCF-7 breast cancer cells.
     Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07397.
     PubMed     Abstract available
     
     
     
365. LISSIDINI G, Nicosia L, Sargenti M, Cucchi MC, et al
     Male breast cancer: a multicenter study to provide a guide for proper management.
     Breast Cancer Res Treat. 2024 Jun 19. doi: 10.1007/s10549-024-07380.
     PubMed     Abstract available
     
     
     
366. NAKAMOTO S, Kajiwara Y, Taniguchi K, Hida AI, et al
     Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14.
     Breast Cancer Res Treat. 2024 Jun 18. doi: 10.1007/s10549-024-07395.
     PubMed     Abstract available
     
     
     
367. HUPPERT LA, Fisch S, Tsopurashvili E, Somepalle SS, et al
     Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study.
     Breast Cancer Res Treat. 2024 Jun 18. doi: 10.1007/s10549-024-07339.
     PubMed     Abstract available
     
     
     
368. NEVEN P, Han S, Borremans K, Van Houdt M, et al
     Re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB).
     Breast Cancer Res Treat. 2024 Jun 16. doi: 10.1007/s10549-024-07399.
     PubMed    
     
     
     
369. HUANG X, Chen C, Lin Y, Wang C, et al
     Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer.
     Breast Cancer Res Treat. 2024 Jun 15. doi: 10.1007/s10549-024-07341.
     PubMed     Abstract available
     
     
     
370. MOKHTARPOUR K, Razi S, Rezaei N
     Ferroptosis as a promising targeted therapy for triple negative breast cancer.
     Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07387.
     PubMed     Abstract available
     
     
     
371. JACKISCH C, Anastasiadou L, Aulmann S, Argyriadis A, et al
     The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score(R) assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer.
     Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07390.
     PubMed     Abstract available
     
     
     
372. RAN X, Hu A, Kuang Y, Wang C, et al
     UM171 suppresses breast cancer progression by inducing KLF2.
     Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07372.
     PubMed     Abstract available
     
     
     
373. BIDISHA B, Sowmya M, Shalini S, Mythri C, et al
     Tamoxifen modulates nutrition deprivation-induced ER stress through AMPK-mediated ER-phagy in breast cancer cells.
     Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07398.
     PubMed     Abstract available
     
     
     
374. BHAVE MA, Quintanilha JCF, Tukachinsky H, Li G, et al
     Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
     Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07376.
     PubMed     Abstract available
     
     
     
375. ALABEDI HH, Ahmed IK, Jamil ASM
     Incidence of local breast cancer recurrence with delayed radiation therapy.
     Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07385.
     PubMed     Abstract available
     
     
     
376. GONCALVES E, Fontes F, Rodrigues JR, Calisto R, et al
     The contribution of second primary cancers to the mortality of patients with a first primary breast cancer.
     Breast Cancer Res Treat. 2024 Jun 13. doi: 10.1007/s10549-024-07361.
     PubMed     Abstract available
     
     
     
377. VAN OLMEN JP, Schrijver AM, Stokkel MPM, Loo CE, et al
     Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer.
     Breast Cancer Res Treat. 2024 Jun 12. doi: 10.1007/s10549-024-07331.
     PubMed     Abstract available
     
     
     
378. ZHANG BX, Brantley KD, Rosenberg SM, Kirkner GJ, et al
     Second primary non-breast cancers in young breast cancer survivors.
     Breast Cancer Res Treat. 2024 Jun 10. doi: 10.1007/s10549-024-07400.
     PubMed     Abstract available
     
     
     
379. LI Y, Long W, Zhou H, Tan T, et al
     Revolutionizing breast cancer Ki-67 diagnosis: ultrasound radiomics and fully connected neural networks (FCNN) combination method.
     Breast Cancer Res Treat. 2024 Jun 9. doi: 10.1007/s10549-024-07375.
     PubMed     Abstract available
     
     
     
380. HOWARD EC, Murray Horwitz ME, Gunn CM, Bak S, et al
     Burden and trajectory of social needs after breast cancer diagnosis at a safety-net hospital.
     Breast Cancer Res Treat. 2024 Jun 8. doi: 10.1007/s10549-024-07389.
     PubMed     Abstract available
     
     
     
381. YIN C, Li H, Zhang B, Liu Y, et al
     Expression of Concern to: RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition.
     Breast Cancer Res Treat. 2024 Jun 6. doi: 10.1007/s10549-024-07392.
     PubMed    
     
     
     
382. FRANCOIS C, Mailliez A, Chretien S, Leguillette C, et al
     Therapeutic impact of (18)F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer.
     Breast Cancer Res Treat. 2024 Jun 5. doi: 10.1007/s10549-024-07386.
     PubMed     Abstract available
     
     
     
383. SCOTT OW, TinTin S, Cavadino A, Elwood JM, et al
     Beta-blocker use and breast cancer outcomes: a meta-analysis.
     Breast Cancer Res Treat. 2024 Jun 5. doi: 10.1007/s10549-024-07263.
     PubMed     Abstract available
     
     
     
384. SHI W, Xu C, Lei P, Sun X, et al
     A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer.
     Breast Cancer Res Treat. 2024 Jun 4. doi: 10.1007/s10549-024-07373.
     PubMed     Abstract available
     
     
     
385. BOYLE L, Lawrenson R, Nosa V, Campbell I, et al
     Ethnic inequities in use of breast conserving surgery and radiation therapy in Aotearoa/New Zealand: which factors contribute?
     Breast Cancer Res Treat. 2024;205:641-653.
     PubMed     Abstract available
     
     
     
386. PERERA D, Pirikahu S, Walter J, Cadby G, et al
     The distribution of breast density in women aged 18 years and older.
     Breast Cancer Res Treat. 2024;205:521-531.
     PubMed     Abstract available
     
     
     
387. LEO CSY, Cheng LJ, Lam XR, He H, et al
     Global prevalence and factors associated with preoperative depression in women undergoing breast surgery: a meta-analysis and meta-regression.
     Breast Cancer Res Treat. 2024;205:425-438.
     PubMed     Abstract available
     
     
     
388. FRANKLIN J, Hayes J, Knippa E, Dogan B, et al
     False negative breast cancers on imaging and associated risk factors: a single institution six-year analysis.
     Breast Cancer Res Treat. 2024;205:507-520.
     PubMed     Abstract available
     
     
     
389. GINZAC A, Molnar I, Durando X, Motte Rouge T, et al
     Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
     Breast Cancer Res Treat. 2024;205:267-279.
     PubMed     Abstract available
     
     
     
390. SHIBAHARA Y, Delabie JMA, Kulkarni S, Grant A, et al
     Primary MALT lymphoma of the breast: pathological and radiological characteristics.
     Breast Cancer Res Treat. 2024;205:387-394.
     PubMed     Abstract available
     
     
     
391. MOKBEL K, Alamoodi M
     Reassessing treatment strategies for DCIS: analysis of survival and recurrence patterns.
     Breast Cancer Res Treat. 2024;205:423-424.
     PubMed    
     
     
     
392. WIMMER K, Hlauschek D, Balic M, Pfeiler G, et al
     Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
     Breast Cancer Res Treat. 2024;205:227-239.
     PubMed     Abstract available
     
     
     
393. ELSON NC, Wernke K, Yoder LM, Fellner AN, et al
     Universal genetic counseling in breast cancer patients significantly improves overall testing rates and improves completion rates in subpopulations.
     Breast Cancer Res Treat. 2024 Jun 1. doi: 10.1007/s10549-024-07329.
     PubMed     Abstract available
     
     
     May 2024
394. ATRE SY, Soulos PR, Kuderer NM, Gross CP, et al
     Characterization of time toxicity in older patients with metastatic breast cancer.
     Breast Cancer Res Treat. 2024 May 31. doi: 10.1007/s10549-024-07379.
     PubMed     Abstract available
     
     
     
395. VAN DER MERWE NC, Buccimazza I, Rossouw B, Araujo M, et al
     Clinical relevance of double heterozygosity revealed by next-generation sequencing of homologous recombination repair pathway genes in South African breast cancer patients.
     Breast Cancer Res Treat. 2024 May 30. doi: 10.1007/s10549-024-07362.
     PubMed     Abstract available
     
     
     
396. LUBARSKY M, Hernandez AE, Collie BL, Westrick AC, et al
     Does structural racism impact receipt of NCCN guideline-concordant breast cancer treatment?
     Breast Cancer Res Treat. 2024 May 29. doi: 10.1007/s10549-024-07245.
     PubMed     Abstract available
     
     
     
397. REWCASTLE E, Skaland I, Gudlaugsson E, Fykse SK, et al
     The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for automated Ki67 scoring in breast cancer.
     Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07352.
     PubMed     Abstract available
     
     
     
398. ISOGAI A, Nozawa K, Nakakami A, Komaki R, et al
     Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
     Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07367.
     PubMed     Abstract available
     
     
     
399. MENES TS, Zippel D, Sklair-Levy M, Friedman E, et al
     Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women.
     Breast Cancer Res Treat. 2024 May 26. doi: 10.1007/s10549-024-07345.
     PubMed     Abstract available
     
     
     
400. SCHWIEGER L, Postlewait LM, Liu Y, Jou S, et al
     Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival.
     Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07368.
     PubMed     Abstract available
     
     
     
401. ZHUO X, Deng H, Qiu M, Qiu X, et al
     Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis.
     Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07350.
     PubMed     Abstract available
     
     
     
402. PEARSON A, Chen J, Dhillon HM, Kiely BE, et al
     Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review.
     Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07364.
     PubMed     Abstract available
     
     
     
403. WHITE O, Dent S, Westbrook K, Lee HJ, et al
     Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer.
     Breast Cancer Res Treat. 2024 May 21. doi: 10.1007/s10549-024-07354.
     PubMed     Abstract available
     
     
     
404. ZHANG Y, Wang H, Zhao H, He X, et al
     Prognostic significance and value of further classification of lymphovascular invasion in invasive breast cancer: a retrospective observational study.
     Breast Cancer Res Treat. 2024 May 21. doi: 10.1007/s10549-024-07318.
     PubMed     Abstract available
     
     
     
405. BARKUR S, Boitor RA, Mihai R, Gopal NSR, et al
     Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery.
     Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07349.
     PubMed     Abstract available
     
     
     
406. GUPTA A, Roy AM, Gupta K, Attwood K, et al
     Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study.
     Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07369.
     PubMed     Abstract available
     
     
     
407. TAKANO T, Masuda N, Ito M, Inoue K, et al
     Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
     Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07333.
     PubMed     Abstract available
     
     
     
408. COLE KM, McGee S, Clemons M, Liu M, et al
     Development and application of a weighted change score to evaluate interventions for vasomotor symptoms in patients with breast cancer using regression trees: a cohort study.
     Breast Cancer Res Treat. 2024 May 19. doi: 10.1007/s10549-024-07360.
     PubMed     Abstract available
     
     
     
409. STRELL C, Smith DR, Valachis A, Woldeyesus H, et al
     Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study.
     Breast Cancer Res Treat. 2024 May 19. doi: 10.1007/s10549-024-07358.
     PubMed     Abstract available
     
     
     
410. BOLDRINI L, Dinapoli L, Boccia E, Caliandro M, et al
     Coping with modesty during radiotherapy for breast cancer: a multicentric study.
     Breast Cancer Res Treat. 2024 May 18. doi: 10.1007/s10549-024-07365.
     PubMed     Abstract available
     
     
     
411. HARVIE M, Livingstone K, McMulllan D, Pegington M, et al
     BE-WEL trial (breast: evaluation of weight and exercise for lymphoedema) testing weight control and exercise programmes for women with breast cancer related lymphoedema: a feasibility trial.
     Breast Cancer Res Treat. 2024 May 17. doi: 10.1007/s10549-024-07356.
     PubMed     Abstract available
     
     
     
412. WOO JW, Han EK, Suh KJ, Kim SH, et al
     Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer.
     Breast Cancer Res Treat. 2024 May 16. doi: 10.1007/s10549-024-07359.
     PubMed     Abstract available
     
     
     
413. SHI X, Sheng Y, Fei H, Wei B, et al
     Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer.
     Breast Cancer Res Treat. 2024 May 15. doi: 10.1007/s10549-024-07355.
     PubMed     Abstract available
     
     
     
414. FREEMAN JQ, Sheade JB, Zhao F, Olopade OI, et al
     Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer.
     Breast Cancer Res Treat. 2024 May 15. doi: 10.1007/s10549-024-07363.
     PubMed     Abstract available
     
     
     
415. GIRO C, Yamada AMTD, Cruz FJSM, do R Barros LA, et al
     Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
     Breast Cancer Res Treat. 2024 May 14. doi: 10.1007/s10549-024-07366.
     PubMed     Abstract available
     
     
     
416. CORIANO M, Tommasi C, Dinh ATL, Needham J, et al
     The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.
     Breast Cancer Res Treat. 2024 May 14. doi: 10.1007/s10549-024-07336.
     PubMed     Abstract available
     
     
     
417. YAMADA M, Jinno H, Naruse S, Isono Y, et al
     Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.
     Breast Cancer Res Treat. 2024 May 13. doi: 10.1007/s10549-024-07370.
     PubMed     Abstract available
     
     
     
418. ROSENBERG SM, Zeng C, An A, Ssebyala SN, et al
     Characterizing "collateral damage" in men and women with metastatic breast cancer (mBC) from diverse racial and ethnic backgrounds in New York City.
     Breast Cancer Res Treat. 2024 May 13. doi: 10.1007/s10549-024-07347.
     PubMed     Abstract available
     
     
     
419. WU Y, Tran T, Dwabe S, Sarkissyan M, et al
     Retraction Note: A83-01 inhibits TGF-beta-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
     Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07371.
     PubMed    
     
     
     
420. ZHANG S, Yang H, Xu Y, Wang S, et al
     Do we need reshape rTNM staging system for ipsilateral breast tumor recurrence of breast cancer? A population-based, propensity score matched cohort study.
     Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07340.
     PubMed     Abstract available
     
     
     
421. FAIRHURST K, McIntosh SA, Cutress RI, Potter S, et al
     Current axillary management of patients with early breast cancer and low-volume nodal disease undergoing primary surgery: results of a United Kingdom national practice survey.
     Breast Cancer Res Treat. 2024 May 10. doi: 10.1007/s10549-024-07328.
     PubMed     Abstract available
     
     
     
422. KLEIN E, Kiechle M, Josipovic A, Anders SI, et al
     Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer.
     Breast Cancer Res Treat. 2024 May 9. doi: 10.1007/s10549-024-07346.
     PubMed     Abstract available
     
     
     
423. LIN B, LeVee A, Cao L, Basho R, et al
     Left ventricular global longitudinal strain is worse in BRCA mutation positive breast cancer patients prior to cancer treatment and premature menopause.
     Breast Cancer Res Treat. 2024 May 8. doi: 10.1007/s10549-024-07344.
     PubMed     Abstract available
     
     
     
424. SAINT K, Nemirovsky D, Lessing A, Chen Y, et al
     Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer.
     Breast Cancer Res Treat. 2024 May 7. doi: 10.1007/s10549-024-07342.
     PubMed     Abstract available
     
     
     
425. CHEN Y, Zhang R, Yan Y, Li H, et al
     Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
     Breast Cancer Res Treat. 2024 May 6. doi: 10.1007/s10549-024-07323.
     PubMed     Abstract available
     
     
     
426. RICHMAN J, Schuster G, Buus R, Lopez-Knowles E, et al
     Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.
     Breast Cancer Res Treat. 2024 May 6. doi: 10.1007/s10549-024-07311.
     PubMed     Abstract available
     
     
     
427. COOMBES RC, Angelou C, Al-Khalili Z, Hart W, et al
     Correction: Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
     Breast Cancer Res Treat. 2024 May 5. doi: 10.1007/s10549-024-07276.
     PubMed    
     
     
     
428. KIMURA T, Takami T, Piao Y, Ntalla I, et al
     Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
     Breast Cancer Res Treat. 2024 May 5. doi: 10.1007/s10549-024-07273.
     PubMed     Abstract available
     
     
     
429. SATHE C, Accordino MK, DeStephano D, Shah M, et al
     Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.
     Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07337.
     PubMed     Abstract available
     
     
     
430. CHIN K, Landen AH, Kovacs A, Warnberg F, et al
     Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study.
     Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07334.
     PubMed     Abstract available
     
     
     
431. SANCHEZ-BAYONA R, Lopez de Sa A, Jerez Gilarranz Y, Sanchez de Torre A, et al
     Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
     Breast Cancer Res Treat. 2024 May 4. doi: 10.1007/s10549-024-07324.
     PubMed     Abstract available
     
     
     
432. BRABENDER D, Ballard A, Kim S, Hovanessian-Larsen L, et al
     Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.
     Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07332.
     PubMed     Abstract available
     
     
     
433. PITTELL H, Calip GS, Pierre A, Ryals CA, et al
     Racialized economic segregation and inequities in treatment initiation and survival among patients with metastatic breast cancer.
     Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07319.
     PubMed     Abstract available
     
     
     
434. NASIF D, Laurito S, Real S, Branham MT, et al
     Exploring the epigenetic profile of ID4 in breast cancer: bioinformatic insights into methylation patterns and chromatin accessibility dynamics.
     Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07343.
     PubMed     Abstract available
     
     
     
435. TENG YT, Wang YA, Dong YH, Liu JJ, et al
     Correction: Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics.
     Breast Cancer Res Treat. 2024 May 2. doi: 10.1007/s10549-024-07335.
     PubMed    
     
     
     
436. BISSELL MB, Keshavarsi S, Fleming R, Au F, et al
     MRI-visualized T2 hyperintense breast lesions: identifying clinical and imaging factors linked to malignant biopsy outcomes.
     Breast Cancer Res Treat. 2024;205:159-168.
     PubMed     Abstract available
     
     
     
437. WUYTS K, Durston V, Morstyn L, Mills S, et al
     Information needs in breast reconstruction after mastectomy: a qualitative analysis of free-text responses from 2077 women.
     Breast Cancer Res Treat. 2024;205:147-157.
     PubMed     Abstract available
     
     
     
438. JORGENSEN SF, Sagstad S, Louro J, Roman M, et al
     Comparisons of assessment pathways after abnormal mammography screening in Denmark, Norway, and Spain.
     Breast Cancer Res Treat. 2024;205:135-145.
     PubMed     Abstract available
     
     
     
439. LUSTBERG M, Fan-Havard P, Wong FL, Hill K, et al
     Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial.
     Breast Cancer Res Treat. 2024;205:61-73.
     PubMed     Abstract available
     
     
     April 2024
440. PIZZAMIGLIO S, Ciniselli CM, de Azambuja E, Agbor-Tarh D, et al
     Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
     Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07299.
     PubMed     Abstract available
     
     
     
441. MORAD A, Johnson K, Bate S, Birkby I, et al
     Ten-year trend analysis of breast cancer, oncoplastic, and reconstructive breast surgery in a single institution (2010-2019), what has not changed?
     Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07294.
     PubMed     Abstract available
     
     
     
442. SCHAFFAR R, Benhamou S, Chappuis PO, Rapiti E, et al
     Risk of first recurrence after treatment in a population-based cohort of young women with breast cancer.
     Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07338.
     PubMed     Abstract available
     
     
     
443. HIJAZI A, Mohanna M, Sabbagh S, Herran M, et al
     Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis.
     Breast Cancer Res Treat. 2024 Apr 29. doi: 10.1007/s10549-024-07321.
     PubMed     Abstract available
     
     
     
444. ROBERTS A, Hallet J, Nguyen L, Coburn N, et al
     Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care.
     Breast Cancer Res Treat. 2024 Apr 27. doi: 10.1007/s10549-024-07282.
     PubMed     Abstract available
     
     
     
445. YADAV SK, Bharath S, Sharma D, Srivastava A, et al
     A systematic review and meta-analysis of diagnostic performance of fluorescein-guided sentinel lymph node biopsy in early breast cancer.
     Breast Cancer Res Treat. 2024 Apr 26. doi: 10.1007/s10549-024-07310.
     PubMed     Abstract available
     
     
     
446. BRADBURY M, Savard MF, Stober C, Clemons L, et al
     Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.
     Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07302.
     PubMed     Abstract available
     
     
     
447. LEE SY, Yoo TK, Kim J, Chung IY, et al
     Characteristics and risk factors of axillary lymph node metastasis of microinvasive breast cancer.
     Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07305.
     PubMed     Abstract available
     
     
     
448. SHI Y, Lu H, Zhang Y
     Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
     Breast Cancer Res Treat. 2024 Apr 24. doi: 10.1007/s10549-024-07317.
     PubMed     Abstract available
     
     
     
449. CHLEBOWSKI RT, Aragaki AK, Pan K, Mortimer JE, et al
     Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.
     Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07307.
     PubMed     Abstract available
     
     
     
450. BERTELSEN BE, Almas B, Fjermeros K, Viste K, et al
     Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
     Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07313.
     PubMed     Abstract available
     
     
     
451. LEONARD S, Jones AN, Newman L, Chavez-MacGregor M, et al
     Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.
     Breast Cancer Res Treat. 2024 Apr 23. doi: 10.1007/s10549-024-07308.
     PubMed     Abstract available
     
     
     
452. DA SILVA JL, de Albuquerque LZ, Rodrigues MES, Thuler LCS, et al
     Ethnic disparities in breast cancer patterns in Brazil: examining findings from population-based registries.
     Breast Cancer Res Treat. 2024 Apr 21. doi: 10.1007/s10549-024-07314.
     PubMed     Abstract available
     
     
     
453. HSU R, Al-Zubeidy B, Flores D, Nazarian A, et al
     Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer.
     Breast Cancer Res Treat. 2024 Apr 20. doi: 10.1007/s10549-024-07295.
     PubMed     Abstract available
     
     
     
454. FERNANDEZ-GONZALEZ S, Falo C, Pla MJ, Campos M, et al
     Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
     Breast Cancer Res Treat. 2024 Apr 18. doi: 10.1007/s10549-024-07274.
     PubMed     Abstract available
     
     
     
455. BALTUSSEN JC, Mooijaart SP, Vulink AJE, Houtsma D, et al
     Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer.
     Breast Cancer Res Treat. 2024 Apr 16. doi: 10.1007/s10549-024-07312.
     PubMed     Abstract available
     
     
     
456. TAN CF, Wang J, Zhong XR, Dai ZL, et al
     Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?
     Breast Cancer Res Treat. 2024 Apr 15. doi: 10.1007/s10549-024-07249.
     PubMed     Abstract available
     
     
     
457. BRANDAO M, Martins-Branco D, De Angelis C, Vuylsteke P, et al
     Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.
     Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07275.
     PubMed    
     
     
     
458. FORTNER RT, Brantley KD, Tworoger SS, Tamimi RM, et al
     Recreational physical activity and breast cancer risk by menopausal status and tumor hormone receptor status: results from the Nurses' Health Studies.
     Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-023-07238.
     PubMed     Abstract available
     
     
     
459. WANG Y, Sun W, Karlsson E, Kang Lovgren S, et al
     Clinical evaluation of deep learning-based risk profiling in breast cancer histopathology and comparison to an established multigene assay.
     Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07303.
     PubMed     Abstract available
     
     
     
460. RUKHSANA, Supty AT, Hussain M, Lee Y, et al
     STK3 higher expression association with clinical characteristics in intrinsic subtypes of breast cancer invasive ductal carcinoma patients.
     Breast Cancer Res Treat. 2024 Apr 9. doi: 10.1007/s10549-024-07248.
     PubMed     Abstract available
     
     
     
461. SULLIVAN M, Lei X, Giordano SH, Chavez-MacGregor M, et al
     Breast cancer (BC) and severe COVID-19 (C-19) outcomes: a matched analysis.
     Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07301.
     PubMed     Abstract available
     
     
     
462. ALLSOPP RC, Guo Q, Page K, Bhagani S, et al
     Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study.
     Breast Cancer Res Treat. 2024 Apr 6. doi: 10.1007/s10549-024-07316.
     PubMed     Abstract available
     
     
     
463. ALHUDIRI I, Nolan C, Ellis I, Elzagheid A, et al
     Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value.
     Breast Cancer Res Treat. 2024 Apr 5. doi: 10.1007/s10549-024-07293.
     PubMed     Abstract available
     
     
     
464. YERUSHALMI R, Pomerantz A, Lewin R, Paluch-Shimon S, et al
     BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.
     Breast Cancer Res Treat. 2024 Apr 3. doi: 10.1007/s10549-024-07271.
     PubMed     Abstract available
     
     
     
465. KONTOS M, Kanavidis P, Kuhn T, Masannat Y, et al
     Targeted axillary dissection: worldwide variations in clinical practice.
     Breast Cancer Res Treat. 2024;204:389-396.
     PubMed     Abstract available
     
     
     
466. AI D, Turashvili G, Gjeorgjievski SG, Wang Q, et al
     Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff.
     Breast Cancer Res Treat. 2024;204:415-422.
     PubMed     Abstract available
     
     
     
467. COBLEIGH MA, Layng KV, Mauer E, Mahon B, et al
     Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.
     Breast Cancer Res Treat. 2024;204:407-414.
     PubMed     Abstract available
     
     
     
468. BAHL M, Deng B
     Impact of pre-operative MRI on surgical management of screening digital breast tomosynthesis-detected invasive lobular carcinoma.
     Breast Cancer Res Treat. 2024;204:397-405.
     PubMed     Abstract available
     
     
     
469. WALSH EA, Post K, Massad K, Horick N, et al
     Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
     Breast Cancer Res Treat. 2024;204:547-559.
     PubMed     Abstract available
     
     
     
470. FLETCHER KA, Alkurashi MH, Lindsay AJ
     Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.
     Breast Cancer Res Treat. 2024;204:631-642.
     PubMed     Abstract available
     
     
     
471. WANG H, Yee D, Potter D, Jewett P, et al
     Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
     Breast Cancer Res Treat. 2024;204:589-597.
     PubMed     Abstract available
     
     
     
472. VAN HEMERT A, van Loevezijn AA, Bosman A, Vlahu CA, et al
     Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.
     Breast Cancer Res Treat. 2024;204:497-507.
     PubMed     Abstract available
     
     
     
473. HARDY-ABELOOS C, Xiao J, Oh C, Barbee D, et al
     Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
     Breast Cancer Res Treat. 2024;204:485-495.
     PubMed     Abstract available
     
     
     
474. BLOMQVIST C, Vehmanen L, Kellokumpu-Lehtinen PL, Huovinen R, et al
     Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study.
     Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07252.
     PubMed     Abstract available
     
     
     
475. MARTINEZ-JANEZ N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, et al
     First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-) breast cancer: The real-life study PALBOSPAIN.
     Breast Cancer Res Treat. 2024 Apr 1. doi: 10.1007/s10549-024-07287.
     PubMed     Abstract available
     
     
     March 2024
476. CAMPBELL EK, Campbell TM, Culakova E, Blanchard L, et al
     A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes.
     Breast Cancer Res Treat. 2024 Mar 30. doi: 10.1007/s10549-024-07284.
     PubMed     Abstract available
     
     
     
477. BURO AW, Nguyen T, Abaskaron M, Haver MK, et al
     Lifestyle interventions with dietary strategies after breast cancer diagnosis: a systematic review.
     Breast Cancer Res Treat. 2024 Mar 29. doi: 10.1007/s10549-024-07278.
     PubMed     Abstract available
     
     
     
478. GULIYEV M, Sen GA, Gulturk I, Majidova N, et al
     The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.
     Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07291.
     PubMed     Abstract available
     
     
     
479. JUNG JJ, Cheun JH, Kim HK, Lee HB, et al
     Comparison of long-term oncologic outcomes of central lumpectomy and conventional breast-conserving surgery for invasive breast cancer: propensity score matching analysis.
     Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07297.
     PubMed     Abstract available
     
     
     
480. TENG YT, Wang YA, Dong YH, Liu JJ, et al
     Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics.
     Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07280.
     PubMed     Abstract available
     
     
     
481. KAPLAN HG, Dowdell AK, Berry AB, Shimol RB, et al
     Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
     Breast Cancer Res Treat. 2024 Mar 24. doi: 10.1007/s10549-024-07270.
     PubMed     Abstract available
     
     
     
482. GODINEZ PAREDES JM, Rodriguez I, Ren M, Orozco A, et al
     Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies.
     Breast Cancer Res Treat. 2024 Mar 23. doi: 10.1007/s10549-024-07300.
     PubMed     Abstract available
     
     
     
483. DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al
     Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains.
     Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07298.
     PubMed     Abstract available
     
     
     
484. COLLIN LJ, Jones J, Nash R, Switchenko JM, et al
     Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.
     Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07279.
     PubMed     Abstract available
     
     
     
485. NASIRI N, Hu M, Hajizadeh M
     Trends in socioeconomic inequalities in breast cancer mortality in Canada: 1992-2019.
     Breast Cancer Res Treat. 2024 Mar 19. doi: 10.1007/s10549-024-07277.
     PubMed     Abstract available
     
     
     
486. AUGUSTINSSON A, Loman N, Ehrencrona H
     Retrospective genetic testing (Traceback) in women with early-onset breast cancer after revised national guidelines: a clinical implementation study.
     Breast Cancer Res Treat. 2024 Mar 16. doi: 10.1007/s10549-024-07288.
     PubMed     Abstract available
     
     
     
487. WU Q, Hatse S, Kenis C, Fernandez-Garcia J, et al
     Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases.
     Breast Cancer Res Treat. 2024 Mar 13. doi: 10.1007/s10549-024-07260.
     PubMed     Abstract available
     
     
     
488. CHUNG HL, Middleton LP, Sun J, Whitman GJ, et al
     Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants.
     Breast Cancer Res Treat. 2024 Mar 12. doi: 10.1007/s10549-024-07261.
     PubMed     Abstract available
     
     
     
489. FARLAND LV, Lind KE, Thomson CA, Saquib N, et al
     Infertility and risk of postmenopausal breast cancer in the women's health initiative.
     Breast Cancer Res Treat. 2024 Mar 9. doi: 10.1007/s10549-024-07257.
     PubMed     Abstract available
     
     
     
490. GION M, Garcia-Mosquera JJ, Perez-Garcia JM, Peg V, et al
     Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
     Breast Cancer Res Treat. 2024 Mar 8. doi: 10.1007/s10549-024-07292.
     PubMed     Abstract available
     
     
     
491. AVILA J, Leone J, Vallejo CT, Lin NU, et al
     Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.
     Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07290.
     PubMed     Abstract available
     
     
     
492. GARCIA-TORRALBA E, Perez Ramos M, Ivars Rubio A, Navarro Manzano E, et al
     Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes.
     Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07286.
     PubMed     Abstract available
     
     
     
493. BAYRAKCEKEN E, Yarali S, Alkan O
     Identify risk factors affecting participation of Turkish women in mammography screening for breast cancer prevention.
     Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07296.
     PubMed     Abstract available
     
     
     
494. FINSTERBUSCH K, van Diest PJ, Focke CM
     Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study.
     Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07281.
     PubMed     Abstract available
     
     
     
495. CAMPBELL TM, Campbell EK, Culakova E, Blanchard LM, et al
     A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes.
     Breast Cancer Res Treat. 2024 Mar 6. doi: 10.1007/s10549-024-07266.
     PubMed     Abstract available
     
     
     
496. SUN H, Kang EY, Chen H, Sweeney KJ, et al
     Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
     Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07256.
     PubMed     Abstract available
     
     
     
497. PLICHTA JK, Thomas SM, Wang X, McDuff SGR, et al
     Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".
     Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07265.
     PubMed     Abstract available
     
     
     
498. KULOTHUNGAN V, Ramamoorthy T, Sathishkumar K, Mohan R, et al
     Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme.
     Breast Cancer Res Treat. 2024 Mar 4. doi: 10.1007/s10549-024-07264.
     PubMed     Abstract available
     
     
     
499. WU Y, Li Z, Lee AV, Oesterreich S, et al
     Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
     Breast Cancer Res Treat. 2024 Mar 1. doi: 10.1007/s10549-024-07255.
     PubMed     Abstract available
     
     
     February 2024
500. DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al
     Development of a core outcome set for breast cancer-related lymphedema: a Delphi study.
     Breast Cancer Res Treat. 2024 Feb 29. doi: 10.1007/s10549-024-07262.
     PubMed     Abstract available
     
     
     
501. HOSSEINI Y, Hadi Sichani P, Moslemi E, Nouri M, et al
     Pro-vegetarian dietary pattern and risk of breast cancer: a case-control study.
     Breast Cancer Res Treat. 2024 Feb 28. doi: 10.1007/s10549-024-07243.
     PubMed     Abstract available
     
     
     
502. VOETS MM, Hassink NS, Veltman J, Slump CH, et al
     Opportunities for personalised follow-up in breast cancer: the gap between daily practice and recurrence risk.
     Breast Cancer Res Treat. 2024 Feb 26. doi: 10.1007/s10549-024-07246.
     PubMed     Abstract available
     
     
     December 2023
503. PACE LE, Fata AM, Cubaka VK, Nsemgiyumva T, et al
     Patients' experiences undergoing breast evaluation in Rwanda's Women's Cancer Early Detection Program.
     Breast Cancer Res Treat. 2023;202:541-550.
     PubMed     Abstract available
     
     
     
504. TURASHVILI G, Gjeorgjievski SG, Wang Q, Ewaz A, et al
     Intraoperative assessment of axillary sentinel lymph nodes by telepathology.
     Breast Cancer Res Treat. 2023;202:423-434.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.